WO1996040731A1 - Pegylated modified proteins - Google Patents
Pegylated modified proteins Download PDFInfo
- Publication number
- WO1996040731A1 WO1996040731A1 PCT/US1996/008995 US9608995W WO9640731A1 WO 1996040731 A1 WO1996040731 A1 WO 1996040731A1 US 9608995 W US9608995 W US 9608995W WO 9640731 A1 WO9640731 A1 WO 9640731A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polyethylene glycol
- mpeg
- immunoglobulin molecule
- protein
- peg
- Prior art date
Links
- 108091005573 modified proteins Proteins 0.000 title description 3
- 102000035118 modified proteins Human genes 0.000 title description 3
- 108060003951 Immunoglobulin Proteins 0.000 claims abstract description 108
- 102000018358 immunoglobulin Human genes 0.000 claims abstract description 108
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 98
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 45
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 42
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 33
- 125000000837 carbohydrate group Chemical group 0.000 claims abstract description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 84
- 238000000034 method Methods 0.000 claims description 61
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 30
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 15
- 238000005571 anion exchange chromatography Methods 0.000 claims description 13
- 238000006243 chemical reaction Methods 0.000 claims description 11
- 238000001542 size-exclusion chromatography Methods 0.000 claims description 9
- 230000002163 immunogen Effects 0.000 claims description 8
- 239000000047 product Substances 0.000 claims description 8
- 230000004071 biological effect Effects 0.000 claims description 7
- 230000021615 conjugation Effects 0.000 claims description 7
- 230000003247 decreasing effect Effects 0.000 claims description 7
- 230000001965 increasing effect Effects 0.000 claims description 7
- 238000005349 anion exchange Methods 0.000 claims description 5
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 4
- 150000003862 amino acid derivatives Chemical class 0.000 claims description 3
- -1 glycine- polyethylene Chemical group 0.000 claims description 3
- 230000001590 oxidative effect Effects 0.000 claims description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 239000007795 chemical reaction product Substances 0.000 claims 2
- 239000003638 chemical reducing agent Substances 0.000 claims 2
- 230000000087 stabilizing effect Effects 0.000 claims 2
- 239000004471 Glycine Substances 0.000 claims 1
- 229940072221 immunoglobulins Drugs 0.000 abstract description 25
- 230000028993 immune response Effects 0.000 abstract description 13
- 239000002671 adjuvant Substances 0.000 abstract description 8
- 108091006006 PEGylated Proteins Proteins 0.000 abstract description 2
- 229920001427 mPEG Polymers 0.000 description 138
- 235000018102 proteins Nutrition 0.000 description 35
- 235000001014 amino acid Nutrition 0.000 description 34
- 150000001413 amino acids Chemical class 0.000 description 33
- 241000699670 Mus sp. Species 0.000 description 32
- 238000002360 preparation method Methods 0.000 description 27
- 239000000427 antigen Substances 0.000 description 23
- 108091007433 antigens Proteins 0.000 description 23
- 102000036639 antigens Human genes 0.000 description 23
- 241000699666 Mus <mouse, genus> Species 0.000 description 21
- 230000006320 pegylation Effects 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 20
- 239000000499 gel Substances 0.000 description 19
- 108010015133 Galactose oxidase Proteins 0.000 description 18
- 206010028980 Neoplasm Diseases 0.000 description 18
- 102000006395 Globulins Human genes 0.000 description 16
- 108010044091 Globulins Proteins 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 238000000746 purification Methods 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 239000011780 sodium chloride Substances 0.000 description 13
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 13
- 150000001720 carbohydrates Chemical group 0.000 description 12
- 101710154606 Hemagglutinin Proteins 0.000 description 11
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 11
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 11
- 101710176177 Protein A56 Proteins 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 238000001212 derivatisation Methods 0.000 description 11
- 238000002649 immunization Methods 0.000 description 11
- 230000003053 immunization Effects 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 10
- 238000009826 distribution Methods 0.000 description 10
- 239000000185 hemagglutinin Substances 0.000 description 10
- 230000005847 immunogenicity Effects 0.000 description 10
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 229920000642 polymer Polymers 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 8
- 241000700605 Viruses Species 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 238000001962 electrophoresis Methods 0.000 description 8
- 230000002255 enzymatic effect Effects 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 238000011725 BALB/c mouse Methods 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 102000011931 Nucleoproteins Human genes 0.000 description 7
- 108010061100 Nucleoproteins Proteins 0.000 description 7
- 229920002684 Sepharose Polymers 0.000 description 7
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 7
- 230000005875 antibody response Effects 0.000 description 7
- NNTOJPXOCKCMKR-UHFFFAOYSA-N boron;pyridine Chemical compound [B].C1=CC=NC=C1 NNTOJPXOCKCMKR-UHFFFAOYSA-N 0.000 description 7
- 210000003022 colostrum Anatomy 0.000 description 7
- 235000021277 colostrum Nutrition 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 description 7
- 210000001165 lymph node Anatomy 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 7
- 229920000936 Agarose Polymers 0.000 description 6
- 241000712431 Influenza A virus Species 0.000 description 6
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- MGNCLNQXLYJVJD-UHFFFAOYSA-N cyanuric chloride Chemical compound ClC1=NC(Cl)=NC(Cl)=N1 MGNCLNQXLYJVJD-UHFFFAOYSA-N 0.000 description 6
- 229930182830 galactose Natural products 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 238000003127 radioimmunoassay Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 210000004408 hybridoma Anatomy 0.000 description 5
- 238000010348 incorporation Methods 0.000 description 5
- 230000036210 malignancy Effects 0.000 description 5
- 229920002401 polyacrylamide Polymers 0.000 description 5
- 239000001632 sodium acetate Substances 0.000 description 5
- 229960004249 sodium acetate Drugs 0.000 description 5
- 235000017281 sodium acetate Nutrition 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 4
- GDTSJMKGXGJFGQ-UHFFFAOYSA-N 3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane Chemical compound O1B([O-])OB2OB([O-])OB1O2 GDTSJMKGXGJFGQ-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 4
- 101710091045 Envelope protein Proteins 0.000 description 4
- ZCOJVESMNGBGLF-GRLWGSQLSA-N Glu-Ile-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O ZCOJVESMNGBGLF-GRLWGSQLSA-N 0.000 description 4
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 101710188315 Protein X Proteins 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 239000011544 gradient gel Substances 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 150000007523 nucleic acids Chemical group 0.000 description 4
- 229960000814 tetanus toxoid Drugs 0.000 description 4
- 241000712461 unidentified influenza virus Species 0.000 description 4
- 241001669573 Galeorhinus galeus Species 0.000 description 3
- 108010002386 Interleukin-3 Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 102000003992 Peroxidases Human genes 0.000 description 3
- 230000006052 T cell proliferation Effects 0.000 description 3
- UKWSFUSPGPBJGU-VFAJRCTISA-N Trp-Leu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N)O UKWSFUSPGPBJGU-VFAJRCTISA-N 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- OHJMTUPIZMNBFR-UHFFFAOYSA-N biuret Chemical compound NC(=O)NC(N)=O OHJMTUPIZMNBFR-UHFFFAOYSA-N 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000011097 chromatography purification Methods 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 238000006911 enzymatic reaction Methods 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000002538 fungal effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 150000003141 primary amines Chemical class 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 238000009827 uniform distribution Methods 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 2
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 2
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- 101100512078 Caenorhabditis elegans lys-1 gene Proteins 0.000 description 2
- 101710132601 Capsid protein Proteins 0.000 description 2
- 101710197658 Capsid protein VP1 Proteins 0.000 description 2
- 102000005600 Cathepsins Human genes 0.000 description 2
- 108010084457 Cathepsins Proteins 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 2
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 2
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- 101710085938 Matrix protein Proteins 0.000 description 2
- 241000712079 Measles morbillivirus Species 0.000 description 2
- 101710127721 Membrane protein Proteins 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 125000003047 N-acetyl group Chemical group 0.000 description 2
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 101710118046 RNA-directed RNA polymerase Proteins 0.000 description 2
- 241000220259 Raphanus Species 0.000 description 2
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 2
- 239000002262 Schiff base Substances 0.000 description 2
- 150000004753 Schiff bases Chemical class 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 101710108545 Viral protein 1 Proteins 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- GZCGUPFRVQAUEE-KCDKBNATSA-N aldehydo-D-galactose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-KCDKBNATSA-N 0.000 description 2
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 2
- 239000001099 ammonium carbonate Substances 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 108010092854 aspartyllysine Proteins 0.000 description 2
- 239000007982 barbital buffer Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 208000035269 cancer or benign tumor Diseases 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- WDEFBBTXULIOBB-WBVHZDCISA-N dextilidine Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)OCC)CCC=C[C@H]1N(C)C WDEFBBTXULIOBB-WBVHZDCISA-N 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 210000000969 egg white Anatomy 0.000 description 2
- 235000014103 egg white Nutrition 0.000 description 2
- 238000013213 extrapolation Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000017290 interleukin-3 production Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000001155 isoelectric focusing Methods 0.000 description 2
- 235000018977 lysine Nutrition 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000009696 proliferative response Effects 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 239000012521 purified sample Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000012723 sample buffer Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- 229960001402 tilidine Drugs 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 108010020532 tyrosyl-proline Proteins 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 101150034533 ATIC gene Proteins 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- PXKLCFFSVLKOJM-ACZMJKKPSA-N Ala-Asn-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O PXKLCFFSVLKOJM-ACZMJKKPSA-N 0.000 description 1
- NMXKFWOEASXOGB-QSFUFRPTSA-N Ala-Ile-His Chemical compound C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 NMXKFWOEASXOGB-QSFUFRPTSA-N 0.000 description 1
- CCDFBRZVTDDJNM-GUBZILKMSA-N Ala-Leu-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O CCDFBRZVTDDJNM-GUBZILKMSA-N 0.000 description 1
- VQAVBBCZFQAAED-FXQIFTODSA-N Ala-Pro-Asn Chemical compound C[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(=O)N)C(=O)O)N VQAVBBCZFQAAED-FXQIFTODSA-N 0.000 description 1
- SAHQGRZIQVEJPF-JXUBOQSCSA-N Ala-Thr-Lys Chemical compound C[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CCCCN SAHQGRZIQVEJPF-JXUBOQSCSA-N 0.000 description 1
- GCTANJIJJROSLH-GVARAGBVSA-N Ala-Tyr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](C)N GCTANJIJJROSLH-GVARAGBVSA-N 0.000 description 1
- MCYJBCKCAPERSE-FXQIFTODSA-N Arg-Ala-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N MCYJBCKCAPERSE-FXQIFTODSA-N 0.000 description 1
- OQCWXQJLCDPRHV-UWVGGRQHSA-N Arg-Gly-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O OQCWXQJLCDPRHV-UWVGGRQHSA-N 0.000 description 1
- NPAVRDPEFVKELR-DCAQKATOSA-N Arg-Lys-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O NPAVRDPEFVKELR-DCAQKATOSA-N 0.000 description 1
- DPLFNLDACGGBAK-KKUMJFAQSA-N Arg-Phe-Glu Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N DPLFNLDACGGBAK-KKUMJFAQSA-N 0.000 description 1
- AIFHRTPABBBHKU-RCWTZXSCSA-N Arg-Thr-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O AIFHRTPABBBHKU-RCWTZXSCSA-N 0.000 description 1
- WCZXPVPHUMYLMS-VEVYYDQMSA-N Arg-Thr-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O WCZXPVPHUMYLMS-VEVYYDQMSA-N 0.000 description 1
- UBKOVSLDWIHYSY-ACZMJKKPSA-N Asn-Glu-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O UBKOVSLDWIHYSY-ACZMJKKPSA-N 0.000 description 1
- OLVIPTLKNSAYRJ-YUMQZZPRSA-N Asn-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)N OLVIPTLKNSAYRJ-YUMQZZPRSA-N 0.000 description 1
- NCXTYSVDWLAQGZ-ZKWXMUAHSA-N Asn-Ser-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O NCXTYSVDWLAQGZ-ZKWXMUAHSA-N 0.000 description 1
- NAPNAGZWHQHZLG-ZLUOBGJFSA-N Asp-Asp-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)N NAPNAGZWHQHZLG-ZLUOBGJFSA-N 0.000 description 1
- SNDBKTFJWVEVPO-WHFBIAKZSA-N Asp-Gly-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(O)=O SNDBKTFJWVEVPO-WHFBIAKZSA-N 0.000 description 1
- KESWRFKUZRUTAH-FXQIFTODSA-N Asp-Pro-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O KESWRFKUZRUTAH-FXQIFTODSA-N 0.000 description 1
- XYPJXLLXNSAWHZ-SRVKXCTJSA-N Asp-Ser-Tyr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O XYPJXLLXNSAWHZ-SRVKXCTJSA-N 0.000 description 1
- 208000034172 Autoimmune Experimental Myasthenia Gravis Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101710117545 C protein Proteins 0.000 description 1
- 101100315624 Caenorhabditis elegans tyr-1 gene Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- QDHHCQZDFGDHMP-UHFFFAOYSA-N Chloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 102100030497 Cytochrome c Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010075031 Cytochromes c Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010056740 Genital discharge Diseases 0.000 description 1
- SZXSSXUNOALWCH-ACZMJKKPSA-N Glu-Ala-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(O)=O SZXSSXUNOALWCH-ACZMJKKPSA-N 0.000 description 1
- UESJMAMHDLEHGM-NHCYSSNCSA-N Gly-Ile-Leu Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O UESJMAMHDLEHGM-NHCYSSNCSA-N 0.000 description 1
- 102100028999 High mobility group protein HMGI-C Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000986379 Homo sapiens High mobility group protein HMGI-C Proteins 0.000 description 1
- HZYHBDVRCBDJJV-HAFWLYHUSA-N Ile-Asn Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(O)=O)CC(N)=O HZYHBDVRCBDJJV-HAFWLYHUSA-N 0.000 description 1
- HDODQNPMSHDXJT-GHCJXIJMSA-N Ile-Asn-Ser Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O HDODQNPMSHDXJT-GHCJXIJMSA-N 0.000 description 1
- KOPIAUWNLKKELG-SIGLWIIPSA-N Ile-His-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N KOPIAUWNLKKELG-SIGLWIIPSA-N 0.000 description 1
- FHPZJWJWTWZKNA-LLLHUVSDSA-N Ile-Phe-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@@H]2C(=O)O)N FHPZJWJWTWZKNA-LLLHUVSDSA-N 0.000 description 1
- ZGKVPOSSTGHJAF-HJPIBITLSA-N Ile-Tyr-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CO)C(=O)O)N ZGKVPOSSTGHJAF-HJPIBITLSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010060231 Insect Proteins Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- SITWEMZOJNKJCH-UHFFFAOYSA-N L-alanine-L-arginine Natural products CC(N)C(=O)NC(C(O)=O)CCCNC(N)=N SITWEMZOJNKJCH-UHFFFAOYSA-N 0.000 description 1
- 241000880493 Leptailurus serval Species 0.000 description 1
- SUPVSFFZWVOEOI-UHFFFAOYSA-N Leu-Ala-Tyr Natural products CC(C)CC(N)C(=O)NC(C)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 SUPVSFFZWVOEOI-UHFFFAOYSA-N 0.000 description 1
- KSZCCRIGNVSHFH-UWVGGRQHSA-N Leu-Arg-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O KSZCCRIGNVSHFH-UWVGGRQHSA-N 0.000 description 1
- DBSLVQBXKVKDKJ-BJDJZHNGSA-N Leu-Ile-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O DBSLVQBXKVKDKJ-BJDJZHNGSA-N 0.000 description 1
- USLNHQZCDQJBOV-ZPFDUUQYSA-N Leu-Ile-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(O)=O USLNHQZCDQJBOV-ZPFDUUQYSA-N 0.000 description 1
- FBNPMTNBFFAMMH-AVGNSLFASA-N Leu-Val-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N FBNPMTNBFFAMMH-AVGNSLFASA-N 0.000 description 1
- FBNPMTNBFFAMMH-UHFFFAOYSA-N Leu-Val-Arg Natural products CC(C)CC(N)C(=O)NC(C(C)C)C(=O)NC(C(O)=O)CCCN=C(N)N FBNPMTNBFFAMMH-UHFFFAOYSA-N 0.000 description 1
- XZNJZXJZBMBGGS-NHCYSSNCSA-N Leu-Val-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O XZNJZXJZBMBGGS-NHCYSSNCSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- GCMWRRQAKQXDED-IUCAKERBSA-N Lys-Glu-Gly Chemical compound [NH3+]CCCC[C@H]([NH3+])C(=O)N[C@@H](CCC([O-])=O)C(=O)NCC([O-])=O GCMWRRQAKQXDED-IUCAKERBSA-N 0.000 description 1
- ZXFRGTAIIZHNHG-AJNGGQMLSA-N Lys-Ile-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CCCCN)N ZXFRGTAIIZHNHG-AJNGGQMLSA-N 0.000 description 1
- YUAXTFMFMOIMAM-QWRGUYRKSA-N Lys-Lys-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O YUAXTFMFMOIMAM-QWRGUYRKSA-N 0.000 description 1
- KFSALEZVQJYHCE-AVGNSLFASA-N Lys-Met-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)N KFSALEZVQJYHCE-AVGNSLFASA-N 0.000 description 1
- SBQDRNOLGSYHQA-YUMQZZPRSA-N Lys-Ser-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SBQDRNOLGSYHQA-YUMQZZPRSA-N 0.000 description 1
- RQILLQOQXLZTCK-KBPBESRZSA-N Lys-Tyr-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(O)=O RQILLQOQXLZTCK-KBPBESRZSA-N 0.000 description 1
- VWPJQIHBBOJWDN-DCAQKATOSA-N Lys-Val-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O VWPJQIHBBOJWDN-DCAQKATOSA-N 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- CAODKDAPYGUMLK-FXQIFTODSA-N Met-Asn-Ser Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O CAODKDAPYGUMLK-FXQIFTODSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- AUEJLPRZGVVDNU-UHFFFAOYSA-N N-L-tyrosyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CC1=CC=C(O)C=C1 AUEJLPRZGVVDNU-UHFFFAOYSA-N 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 241001524178 Paenarthrobacter ureafaciens Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- NJJBATPLUQHRBM-IHRRRGAJSA-N Phe-Pro-Ser Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)N)C(=O)N[C@@H](CO)C(=O)O NJJBATPLUQHRBM-IHRRRGAJSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- OOLOTUZJUBOMAX-GUBZILKMSA-N Pro-Ala-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O OOLOTUZJUBOMAX-GUBZILKMSA-N 0.000 description 1
- WVOXLKUUVCCCSU-ZPFDUUQYSA-N Pro-Glu-Ile Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WVOXLKUUVCCCSU-ZPFDUUQYSA-N 0.000 description 1
- MCWHYUWXVNRXFV-RWMBFGLXSA-N Pro-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@@H]2CCCN2 MCWHYUWXVNRXFV-RWMBFGLXSA-N 0.000 description 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- HEQPKICPPDOSIN-SRVKXCTJSA-N Ser-Asp-Tyr Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HEQPKICPPDOSIN-SRVKXCTJSA-N 0.000 description 1
- BUYHXYIUQUBEQP-AVGNSLFASA-N Ser-Phe-Glu Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CO)N BUYHXYIUQUBEQP-AVGNSLFASA-N 0.000 description 1
- PCJLFYBAQZQOFE-KATARQTJSA-N Ser-Thr-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CO)N)O PCJLFYBAQZQOFE-KATARQTJSA-N 0.000 description 1
- ZKOKTQPHFMRSJP-YJRXYDGGSA-N Ser-Thr-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ZKOKTQPHFMRSJP-YJRXYDGGSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241001147693 Staphylococcus sp. Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- DCLBXIWHLVEPMQ-JRQIVUDYSA-N Thr-Asp-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 DCLBXIWHLVEPMQ-JRQIVUDYSA-N 0.000 description 1
- UBDDORVPVLEECX-FJXKBIBVSA-N Thr-Gly-Met Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(O)=O UBDDORVPVLEECX-FJXKBIBVSA-N 0.000 description 1
- NCXVJIQMWSGRHY-KXNHARMFSA-N Thr-Leu-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N)O NCXVJIQMWSGRHY-KXNHARMFSA-N 0.000 description 1
- WCRFXRIWBFRZBR-GGVZMXCHSA-N Thr-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 WCRFXRIWBFRZBR-GGVZMXCHSA-N 0.000 description 1
- 241000251221 Triakidae Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- BURPTJBFWIOHEY-UWJYBYFXSA-N Tyr-Ala-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 BURPTJBFWIOHEY-UWJYBYFXSA-N 0.000 description 1
- KLQPIEVIKOQRAW-IZPVPAKOSA-N Tyr-Thr-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N)O KLQPIEVIKOQRAW-IZPVPAKOSA-N 0.000 description 1
- ZXAGTABZUOMUDO-GVXVVHGQSA-N Val-Glu-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N ZXAGTABZUOMUDO-GVXVVHGQSA-N 0.000 description 1
- ZTKGDWOUYRRAOQ-ULQDDVLXSA-N Val-His-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)O)N ZTKGDWOUYRRAOQ-ULQDDVLXSA-N 0.000 description 1
- ZRSZTKTVPNSUNA-IHRRRGAJSA-N Val-Lys-Leu Chemical compound CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)C(C)C)C(O)=O ZRSZTKTVPNSUNA-IHRRRGAJSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 108010070783 alanyltyrosine Proteins 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
- 108010018691 arginyl-threonyl-arginine Proteins 0.000 description 1
- 108010093581 aspartyl-proline Proteins 0.000 description 1
- 108010047857 aspartylglycine Proteins 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- TWFZGCMQGLPBSX-UHFFFAOYSA-N carbendazim Chemical compound C1=CC=C2NC(NC(=O)OC)=NC2=C1 TWFZGCMQGLPBSX-UHFFFAOYSA-N 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000991 chicken egg Anatomy 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- FSXRLASFHBWESK-UHFFFAOYSA-N dipeptide phenylalanyl-tyrosine Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FSXRLASFHBWESK-UHFFFAOYSA-N 0.000 description 1
- UQGFMSUEHSUPRD-UHFFFAOYSA-N disodium;3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane Chemical compound [Na+].[Na+].O1B([O-])OB2OB([O-])OB1O2 UQGFMSUEHSUPRD-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 1
- 108010032388 glycyl-prolyl-glycyl-arginyl-alanyl-phenylanine Proteins 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- JARKCYVAAOWBJS-UHFFFAOYSA-N hexanal Chemical group CCCCCC=O JARKCYVAAOWBJS-UHFFFAOYSA-N 0.000 description 1
- 108010025306 histidylleucine Proteins 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 108010044374 isoleucyl-tyrosine Proteins 0.000 description 1
- 244000145841 kine Species 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 108010009298 lysylglutamic acid Proteins 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000005065 mining Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000010915 one-step procedure Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108010093296 prolyl-prolyl-alanine Proteins 0.000 description 1
- 239000011546 protein dye Substances 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000005932 reductive alkylation reaction Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001005 suppressogenic effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 108010033670 threonyl-aspartyl-tyrosine Proteins 0.000 description 1
- 108010061238 threonyl-glycine Proteins 0.000 description 1
- 108010031491 threonyl-lysyl-glutamic acid Proteins 0.000 description 1
- 230000003614 tolerogenic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Definitions
- the present invention relates to pegylated proteins, including modified immunoglobulin molecules mildly derivatized with polyethylene glycol. Such "pegylated" immunoglobulins may be used to produce an enhanced immune response in the absence of adjuvant.
- the present invention relates to proteins conjugated to polyethylene glycol via carbohydrate residues.
- PEG Polyethylene glycol
- mPEG monomethoxypolyethylene glycol
- bovine serum catalase mildly derivatized with mPEG was found to retain full enzymatic activity in vitro (Abuchows i et al., 1977, J. Biol. Chem. 252:3582) . Thereafter, various enzymes derivatized with mPEG were used for enzyme substitution and cancer therapy (Abuchowski et al. , 1984, Cancer Biochem. Biophys. 2:175). Proteins of therapeutic use such as recombinant interleukin 2 ("rIL-2”) were also derivatized with mPEG and showed increased potency to stimulate specific CTL activity in a murine sarcoma model (Katre et al., 1987, Proc. Natl.
- pegylation Mild conjugation to PEG (“pegylation") was used to increase the half-life of tumor-specific intact immunoglobulin molecules and F(ab , ) 2 fragments without significant alteration of the binding capacity to tumor antigens (Kitamura et al., 1990, Biochem. Biophy. Res. Commun. 2:1387). Pegylated anti-tumor antibodies were able to enhance tumor localization (Kitamura et al., 1991, Cancer Res. £>1: 4310) .
- pegylated immuno ⁇ globulins The increase in half-life of pegylated immuno ⁇ globulins was correlated with resistance to proteolytic enzymes and with low clearance rate through the kidney. Indeed, when seven percent of the primary amines of human immunoglobulin were substituted with mPEG, the conjugates were resistant to trypsin digestion, and at 14 percent substitution they were resistant to pepsin digestion (Cunningham-Ruddles et al., J. Immunol. Methods 152:177) . This indicated that pegylated immuno ⁇ globulin may be used in oral administration in the treatment of some gastrointestinal diseases.
- the present invention relates to proteins which are covalently conjugated to polyethylene glycol ("pegylated”) .
- the pre ⁇ sent invention provides for pegylated immunoglobulins.
- immunoglobulin containing an immunogenic heterologous peptide corresponding to a T cell or a B cell epitope may be pegylated to increase the half-life of the immunoglobulin without substantially decreasing the biological activity of the immunoglobulin molecule or the immunogenicity of the heterologous peptide.
- Such pegylated immunoglobulins containing heterologous peptide may be used to produce an enhanced immune response to the heterologous peptide in a subject.
- Such pegylated immunoglobulins may also be used to elicit an immune response to the heterologous peptide in a subject in the absence of adjuvant.
- the present invention provides for proteins that are conjugated to poly ⁇ ethylene glycol via carbohydrate residues, and for methods of producing such "glycopegylated" proteins.
- Proteins which may be pegylated in this manner include, but are not limited to, immunoglobulin, antigenic pro ⁇ teins, therapeutic proteins, and proteins used for diagnostic purposes.
- FIG. 1 Blood clearance of native and pegylated Ig-HA. Mice (three per group) were injected intravenously with 125 I-labeled Ig-HA or Ig-HA-mPEG. The mice were rested for 15 minutes to allow uniform distribution of radiolabeled material and then blood samples were collected at various intervals of time. Radioactivity content of total blood volume was estimated and considered as the total radioactivity injected (TRI) . Blood samples were collected at indi ⁇ cated times and total residual radioactivity (TRR) was estimated. The percent of residual activity was esti ⁇ mated according to the following formula [1-(TRR/TRI) ] x 100. Each point represents the mean ⁇ SD of three mice.
- FIG. 1 In vivo proteolysis of native and pegylated Ig-HA. Serum samples from mice injected intravenously with 125 I-labeled Ig-HA or Ig-HA-mPEG (20 x 10 6 cpm/mouse) were collected at indicated times after injection and 5/xl of serum was run on an 8-17% gradient polyacrylamide gel. Separated material was electrotransferred onto PVDF membranes and exposed to Kodak X-OMAT films. The left panel (A) shows the pat ⁇ tern of in vivo degradation, over time, of samples collected from a mouse injected with Ig-HA. The right panel (B) shows the pattern of in vivo degradation, from a mouse injected with Ig-HA-mPEG.
- A shows the pat ⁇ tern of in vivo degradation, over time, of samples collected from a mouse injected with Ig-HA.
- the right panel (B) shows the pattern of in vivo degradation, from a mouse injected with Ig-HA-
- FIG. 3 Tissue distribution of native and pegylated Ig-HA.
- Groups of seven mice each (15-17 g weight) were injected intravenously with 125 I-labeled Ig-HA or Ig-HA-mPEG. The mice were rested for 15 min to allow uniform distribution of the labeled material and blood samples were collected. Fragments of vis ⁇ ceral organs (liver (A) ; spleen (B) ; Kidney (C) ; lung (D)) were then resected at indicated times after injec ⁇ tion.
- the tissue distribution of native or pegylated Ig-HA was estimated as index of distribution (% ID) . Each point represents % ID for a mouse corresponding to the indicated time after injection.
- FIG. 4 I__ vitro activation of HA110-120 specific LDl-24 T cell hybridomas by native and pegy ⁇ lated Ig-HA.
- Graded amounts of chromatographically purified Ig-HA, Ig-HA-mPEG and Ig-NP-mPEG were incu ⁇ bated with 2PK3 antigen presenting cells ("APCs"; 10 4 ) and LDl-24 T hybridoma cells (2 x 10 4 ) .
- APCs 2PK3 antigen presenting cells
- LDl-24 T hybridoma cells (2 x 10 4 ) .
- Activation of LDl-24 T cells was assessed 48 hours later by measuring IL-3 production in the cell supernatant using IL-3 dependent DA-1 cells (15 x 10 4 ) and MTT assay. Each point represents the mean of quadruplets plus or minus SD.
- FIG. 5 I ⁇ vivo priming of HA110-120 specific T cells by native and pegylated Ig-HA.
- [ 3 H]-thymidine was added for 18 hours and incorporation was measured.
- Panels (a) and (b) represent the [ 3 H]-thymidine incorporation by lymph node cells from mice immunized with Ig-HA in saline and CFA, respectively.
- Panels (c) and (d) represent the [ 3 H]-thymidine incorporation by lymph node cells from mice immunized with Ig-HA-mPEG in saline and CFA, respectively.
- stimulation in vitro was carried out with graded amounts (0.5, 1, 5 and lO ⁇ g/ml) of Ig-HA, Ig-NP, HA110-120 synthetic pep ⁇ tide, NP147-161 synthetic peptide or UV-inactivated PR8 virus.
- [ 3 H]-thymidine incorporation upon in vitro stimulation with concanavalin A ("ConA") for three days is also indicated. Each point represents the mean of quadruplet wells plus or minus SD, after subtraction of cpm obtained in the absence of antigen.
- ConA concanavalin A
- FIG. 6 AntiJody response of mice immunized with native and pegylated Ig-V 3 C.
- Groups of three mice were immunized with either Ig-V 3 C (open circles) or Ig-V 3 C-mPEG closed circles) , bled at indi ⁇ cated intervals of time and the titers of antibodies to V 3 C peptide (panels a, b, c and d) and to human iso- typic determinants (panels e, f, g and h) were deter ⁇ mined.
- mice were immunized sub ⁇ cutaneously with lOO ⁇ g of either Ig-V 3 C or Ig-V 3 C-mPEG emulsified in CFA and boosted two weeks later with 50 ⁇ g of antigens in Incomplete Freund's adjuvant (IFA) .
- IFA Incomplete Freund's adjuvant
- FIG. 7 Separation of Ig-HA-mPEG conjugates from unpegylated Ig-HA by HPLC on Q300 anion exchange column .
- Panel (a) shows the elution profile of the material collected from peak 1 in Figure 10 and loaded onto the Q300 column.
- Panel (b) shows a control elution profile of a preparation of unpegylated Ig-HA.
- Figure 8 Detection of residual mPEG in Algs- mPEG preparations by electrophoresis on Titan agarose Gel. Samples collected at various steps of purification were run on duplicate Titan gels and either stained with Coomassie/Ponceau (R250) or precipitated with TCA. Lane 1, IgHA-mPEG conjugate after purification on anion-exchange HPLC; lane 2, unpegylated IgHA; lane 3, mPEG 5,000 (4 x 10 " M) ; lane 4, IgHA-mPEG conjugate after first step of purification by gel filtration on AcA44 (not done in Coomassie staining) .
- FIG. 9 Analysis of homogeneity of Alg-mPEG preparations by SDS-PAGE. Samples collected subsequent to purification on anion-exchange HPLC were analyzed on 4-15% polyacrylamide gradient PhastGels (Pharmacia) under nonreducing conditions. Lanes l and 4, unpegy ⁇ lated Ig-HA and Ig-V 3 C, respectively; lanes 2 and 4, Ig-HA-mPEG and Ig-V 3 C-mPEG, respectively (content of peak 2 in Figure 8) ; and lanes 3 and 6 highly derivatized Ig-HA and Ig-V 3 C (content of peak l in Figure 8) . Figure 10.
- FIG. 1 Diagram of synthesis of Ig-Gal- PEG conjugates.
- FIG. 12 SDS-PAGE Analysis of Ig-Gal-PEG Conjugates. Chromatographic purified samples of the Ig-gal-PEG conjugates were analyzed on 4-20% poly ⁇ acrylamide gradient gels under reducing and non- reducing conditions and stained with Coomassie R-250. Lanes 1 and 2 show reduced unpegylated and reduced pegylated human IgA from colostrum.
- FIG. 13 Isoelectric Focusing of Ig-Gal- PEG Conjugates. Chromatographic purified samples of the Ig-Gal-PEG conjugates were analyzed on PAG plates with a pH gradient between 3 and 10, as described in Section 8. Lane l shows the pi markers, pH 3-10, and lanes 2 and 3, pegylated and unpegylated human IgA from colostrum, respectively.
- FIG. 14 Titan Gel Electrophoresis of Ig- Gal-PEG Conjugates.
- Ig-Gal-PEG conjugates were anal ⁇ yzed by agarose electrophoresis as described in Section 8.
- Lane 1 represents glycopegylated human IgA and lane 2 represents native human IgA.
- FIG. 15 Estimation of "Gal Equivalents" on Native Igs.
- the Gal residues of human IgA from colostrum and rat IgG2b anti-mouse k chain mAb were determined by measuring GAO enzymatic activity as com ⁇ pared to known amounts of D-galactose, as described in Section 8. Dotted plot represents GAO activity on D- galactose as a substrate.
- the corresponding Gal resi ⁇ dues per molecule of Ig were cal ⁇ culated according to data obtained from GAO activity on the monosaccharide substrate (lower side of the abscissa) .
- the present invention relates to immunoglobulin molecules modified to contain a heterologous peptide, which are covalently conjugated to polyethylene glycol ("pegylated").
- the heterologous peptide may be an immunogenic peptide or other biolocially active peptide.
- immunogenic as used herein, is construed to mean that the heterologous peptide occur ⁇ ring in the modified immunoglobulin molecule is capable of eliciting a specific immune response.
- the immunogenic heterologous peptide is a B cell epi ⁇ tope or a T cell epitope.
- the invention is based, at least in part, on the discovery that the stability of such immuno ⁇ globulins and/or their ability to enhance the immune response is augmented when the modified immunoglobulins are mildly derivatized with polyethylene glycol ("pegy ⁇ lated") .
- mild derivatization of the immunoglobulins containing a B cell or a T cell epitope may significantly increase the half-life of the immuno ⁇ globulin molecules without substantially decreasing the biological activity of the immunoglobulin molecule or the immunogenicity of the heterologous peptide.
- a substantial decrease of the biological activity of an immunoglobulin molecule refers to the situation where the biological activity of the immuno ⁇ globulin has decreased to an extent where the immuno ⁇ globulin loses its ability to effectively deliver the B cell or a T cell epitope to immune cells.
- a "substan ⁇ tial decrease" in the immunogenicity of a B cell or a T cell epitope refers to the effective inability of the epitope to elicit a specific immune response.
- Mild pegylation of immunoglobulin molecules containing a B cell epitope or a T cell epitope enhances the immunogenicity of the epitope and may obviate the requirement for adjuvants.
- the beneficial effects of pegylation of various immunoglobulins is set forth in Example Sections 6 and 7, below.
- the present invention further provides for a method of pegylation which conjugates PEG to carbo- hydrate residues of an immunoglobulin molecule, thereby minimizing structural distortion of the peptide back ⁇ bone of the immunoglobulin or any heterologous epitopes comprised therein.
- a working example of such "glyco- pegylation" is set forth in Example Section 8, below.
- the present invention may be applied to any immunoglobulin molecule, including human and nonhuman immunoglobulin molecules, immunoglobulin molecules con ⁇ taining both human and nonhuman portions, and immuno ⁇ globulins of any class (e.g. IgG, IgM, IgD, IgE, or IgA) and any specificity.
- immunoglobulin molecules including human and nonhuman immunoglobulin molecules, immunoglobulin molecules con ⁇ taining both human and nonhuman portions, and immuno ⁇ globulins of any class (e.g. IgG, IgM, IgD, IgE, or IgA) and any specificity.
- Such immunoglobulin molecules are modified to contain a heterologous peptide.
- a heterologous peptide may be a B-cell or T-cell epitope of an antigen, a cytokine, a toxin, or an idiotypic determinant, which has been covalently linked to the immunoglobulin molecule.
- Such covalent linkage may be accomplished by genetic engineering techniques in which a nucleic acid sequence encoding the heterologous peptide is inserted into a nucleic acid sequence encoding the immuno ⁇ globulin molecule. Most preferably, the nucleic acid sequence encoding the heterologous peptide replaces a similarly sized sequence of a complementarity deter ⁇ mining region ("CDR") of the immunoglobulin molecule, as set forth in United States patent application Serial No. 08/363,276.
- CDR complementarity deter ⁇ mining region
- the engineered nucleic acid may then be incorporated into a suitable expression vector and expressed as a protein comprising an immunoglobulin molecule covalently linked to the heterologous peptide. More than one heterologous peptide (of the same or dif ⁇ ferent variety) may be incorporated into the immuno ⁇ globulin by this method.
- the genetically engineered immunoglobulin molecule contains a heterologous pep ⁇ tide, such as a T cell or a B cell epitope, in place of a CDR loop of the immunoglobulin molecule, the CDR loop having been deleted and replaced with the heterogenous peptide.
- the CDR loop that is deleted and replaced with the heterologous peptide may be located in either the heavy or the light chain and may be CDR1, CDR2, or CDR3 loop.
- the genetically engineered immunoglobulin molecule containing a heterologous peptide may be, for example, a humanized immunoglobulin molecule, an exam ⁇ ple of which is an immunoglobulin molecule genetically engineered to comprise the constant regions of a human immunoglobulin and the variable regions of a murine immunoglobulin.
- the heterologous peptide may be linked to the immunoglobulin molecule by enzymatic means.
- the heterologous peptide may be linked to the immuno ⁇ globulin molecule via a carbohydrate residue of the immunoglobulin molecule, as set forth in United States Patent Application Serial No. 08/441,328, using a method analogous to the linkage of PEG to enzymatically oxidized carbohydrate residues of an immunoglobulin molecule, as exemplified in Section 8, below.
- heterologous peptide may be conjugated to enzymatically oxidized carbohydrate groups (e.g.
- peptides may comprise at least 2 and preferably at least five amino acid residues and may comprise immunogenic epitopes of antigens; suitable antigens include, but are not limited to, antigens associated with pathogens, tumor cells, or "non-self" antigens with respect to a particular individual.
- Peptides may be biologically active themselves (for example, growth factors, toxins, immune mediators, differentiation factors etc.) or be portions of bio ⁇ logically active proteins.
- the peptide may comprise all, or a portion, of IL-1 or tetanus toxoid.
- peptides which may be used according to the invention include B cell epitopes.
- B cell epitope refers to a peptide, including a peptide comprised in a larger protein, which is able to bind to an immuno ⁇ globulin receptor of a B cell and participate in the induction of antibody production by the B cell.
- V3 loop the hypervariable region 3 loop of the envelope protein of human immunodeficiency virus (“HIV") type 1 is known to be a B cell epitope.
- sequence of this epitope varies, the following consensus sequence, corresponding to residues 301-319 of HIV-1 gpl20 protein, has been obtained: Arg- Lys-Ser-Ile-His-Ile-Gly-Pro-Gly-Arg-Ala-Phe-Tyr-Thr- Thr-Gly-Glu-Ile-Ile (SEQ ID N0:1).
- B cell epitopes which may be used according to the invention include, but are not limited to, epitopes associated with influenza virus strains, such as Trp-Leu-Thr-Lys-Lys-Gly-Asp-Ser- Tyr-Pro (SEQ ID NO:2), which has been shown to be an immunodominant B cell epitope in site B of influenza HA1 hemagglutinin, the epitope Trp-Leu-Thr-Lys-Ser-Gly- Ser-Thr-Tyr-Pro (H3; SEQ ID NO:3), and the epitope Trp-Leu-Thr-Lys-Glu-Gly-Ser-Asp-Tyr-Pro (H2; SEQ ID NO:4; Li et al., 1992, J.
- epitopes associated with influenza virus strains such as Trp-Leu-Thr-Lys-Lys-Gly-Asp-Ser- Tyr-Pro (SEQ ID NO:2), which
- Virol. 16:399-404 an epitope of F protein of measles virus (residues 404- 414; Ile-Asn-Gln-Asp-Pro-Asp-Lys-Ile-Leu-Thr-Tyr; SEQ ID NO:5) Parlidos et al., 1992, Eur. J. Immunol. 22.:2675-2680) ; an epitope of hepatitis virus pre-Sl region, from residues 132-145 (Leclerc, 1991, J. Immunol.
- B cell epitopes which may be used are known or may be identified by methods known in the art, as set forth in Caton et al., 1982, Cell 21:417-427.
- peptides which may be used may be T cell epitopes.
- T cell epitope refers to a pep ⁇ tide, including a peptide comprised in a larger pro ⁇ tein, which may be associated with MHC self antigens and recognized by a T cell, thereby functionally activating the T cell.
- a peptide may comprise a T h epi ⁇ tope, which, in the context of MHC class II self anti ⁇ gens, may be recognized by a helper T cell and thereby promote the facilitation of B cell antibody production via the T h cell.
- influenza A hemagglutinin (HA) protein bears, at amino acid residues 110-120, a T h epitope having the amino acid sequence Ser-Phe-Glu-Arg-Phe-Glu-Ile-Phe-Pro-Lys- Glu (SEQ ID NO:7) .
- T cell epitopes include, but are not limited to, two promiscuous epi ⁇ topes of tetanus toxoid, Asn-Ser-Val-Asp-Asp-Ala-Leu- Ile-Asn-Ser-Thr-Lys-Ile-Tyr-Ser-Tyr-Phe-Pro-Ser-Val (SEQ ID NO:8) and Pro-Glu-Ile-Asn-Gly-Lys-Ala-Ile-His- Leu-Val-Asn-Asn-Glu-Ser-Ser-Glu (SEQ ID NO:9; Ho et al., 1990, Eur. J. Immunol.
- the peptide comprises a T cell epitope
- APC antigen presenting cell
- the lipophilic quadruplet Ala-Ala- Ala-Leu SEQ ID NO:15
- the lipophilic quadruplet Ala-Ala- Ala-Leu that contains the cleavage site for cathepsins (Yonezawa et al., 1987, Arch. Biochem. Biophys 256:499) .
- lysosomal cathepsins play an important role in processing of exogenous molecules.
- Peptides for use according to the invention may be purified from natural sources, or may be recom- binantly and/or chemically synthesized. They may con- tain amino acid analogs, and may be detectably label ⁇ led.
- Immunoglobulins may be covalently linked to polyethylene glycol ("pegylated") by any method known in the art for conjugating polyethylene glycol to a protein or to a carbohydrate (see Section 5.3, infra.
- the molar ratio of PEG residues per immunoglobulin is at least 50 to 1.
- the chemically activated PEG used to pegylate the immunoglobulin molecules of the present invention may be any of the many activated forms of PEG known to those skilled in the art, including but not limited to activated mPEG 5000 or activated mPEG 3500.
- the particular activated PEG used may be of any of the molecular weights known to those skilled in the art. It is preferred that PEG activa ⁇ tion be achieved via succinimide or triazine.
- chemically activated PEG i.e., PEG rendered capable of covalent linkage by chemical means
- PEG rendered capable of covalent linkage by chemical means
- a 50-fold molar excess of 2,4,6-trichloro-s- triazine activated mPEG 5000 also known as 2-0- monomethoxypolyphenylene glycol 4,6-dichloro-S-tria- zine, or another size or activated form of PEG, may be added to a solution of the immunoglobulin to be con ⁇ jugated in 0.1M tetraborate buffer, pH 9.6, stirred vigorously for four hours at room temperature (in one specific nonlimiting embodiment, at least 18°C) , and then concentrated using an ultrafiltration/concen- tration apparatus having a 100,000 molecular weight cut off (“MWCO”) .
- MWCO 100,000 molecular weight cut off
- a 50-fold molar excess of 2,4,6-trichloro-s-triazine activated mPEG 5000 may be added to a solution of 10 mg of the immunoglobulin to be conjugated in 10 ml of 0.1M tetraborate buffer, pH 9.6, stirred vigorously for four hours at room temperature, and then concentrated to 1.5 ml in a CENTREX UF-2 ultraconcentrator of 100,000 MWCO (Schleicher & Schuell) .
- the amount of pegylation be effective for increasing the half-life of the immunoglobulin molecule without substantially decreasing the bio ⁇ logical activity of the immunoglobulin molecule or the immunogenicity of the heterologous peptide.
- the amount of pegylation should be effective for increasing the immunogenicity of the heterogenous pep ⁇ tide without substantially decreasing the biological activity of the immunoglobulin molecule.
- the amount of pegylation be effective for conferring to the immunoglobulin molecule an ability to elicit a immune response to the heterologous peptide in a subject, when the immunoglobulin molecule is introduced into the subject without an adjuvant.
- the pegylation occurs via epsilon amino groups of the lysine residues that are accessible for pegylation
- approximately 4 to 10 % of all the accessible epsilon amino groups of lysine residues are pegylated.
- approximately 6 to 8 % of the accessible epsilon amine groups of lysine residues are pegylated.
- the degree of mPEG derivatization may be estimated by fluorescamine assay as described in Cunningham-Ruddles et al., 1992, J. Immunol. Methods 152:177.
- graded amounts e.g. 0.25, 0.5, and l microgram
- immuno- globulin-mPEG conjugate may be dissolved in 25 micro ⁇ liters of PBS and mixed with an equal volume of fresh fluorescamine in acetone (150g/ml) . Samples may then be incubated for 5 minutes at room temperature and then adjusted to 1 ml with PBS. The absorbance may then be measured at 475 nm emission versus 390 nm excitation and the percent of pegylated residues may be estimated by the formula:
- Preparations of PEG-immunoglobulin conjugates may then be purified to substantially remove unreacted PEG as well as any undesirable products of the con ⁇ jugation process, such as residual adducts.
- mPEG 5000 where PEG is conjugated to immunoglobulin via lysine residues using 2,4,6-trichloro-s-triazine activated mPEG 5000, as set forth above, the following two-step method of purification may be used.
- residual unreacted mPEG may be removed by, for example, size exclusion chromatography, ultrafiltration, or dialysis followed by either anion exchange chromatography, hydrophobic chromatography, or reverse phase chroma ⁇ tography., for example, but not by way of limitation, on an AcA44 Ultogel column which has been equilibrated with 0.1 M ammonium hydrogencarbonate, pH 8.5 and flow- rate of 0.4 ml/min.
- unreacted mPEG may be removed as follows.
- the products of conjugation reac ⁇ tion may be applied to an AcA44 Ultrogel filtration column (80 x 1.6 cm) which has been equilibrated with 0.1M NH 4 HC0 3 , pH 8.5 and a flow rate of 0.4 ml per minute.
- Fractions of eluate may then be collected at 4 minute intervals, dried by speed vacuum centrifugation and resuspended in 0.5 ml of 5 mM sodium acetate, pH 5.0. Each fraction may then be analyzed for protein content by, for example, Biuret micro assay, and for the presence of free hydrolyzed mPEG by Nessler's reagent, as described in Wilkinson et al., 1987, Immunol. Lett. .15:17-22. Fractions of the conjugates which are found to be free of hydrolyzed mPEG may then be subjected to a second chromatography step to remove residual adducts.
- fractions of conjugates found to be free of hydrolyzed mPEG may then be applied to a Q300 anion exchange HPLC column (or a similar anion exchange column) which has been equil ⁇ ibrated with 5 mM sodium acetate, pH 5 using a 45 minute linear gradient from 5 to 500 mM sodium acetate, pH 5, and a flow rate of 0.5 ml/min.
- Fractions from the Q300 column may then be dialyzed in Spectrapor bags with 75,000 MWCO against PBS and concentrated in CENTREX UF-2 tubes. Other methods, such as those set forth for removing unreacted PEG, could also be used to remove residual adducts.
- Fractions containing useful PEG-IG conjugates may be identified, for example, by fluorescamine assay, mass spectroscopy, proton NMR, or SDS-PAGE.
- the present invention further provides for pegylation of non-immunoglobulin molecules, where polyethylene glycol is conjugated to a non-immunoglo ⁇ bulin molecule via carbohydrate residues, using enzym ⁇ atic methods as set forth in section 5.3., infra.
- non-immunoglobulin molecules which may be pegylated in this manner include, but are not limited to, proteins which are naturally or arti- ficially glycosylated. Proteins which are, or may be rendered, glycosylated include bacterial, viral, pro- tozoal, yeast, funal or insect proteins, proteins expressed in cells of lower or higher vertebrates, receptor proteins, signal transductions proteins, cyto ⁇ kines, enzymes, membrane proteins, etc.
- the present invention also provides for an enzymatic method which may be used to couple PEG to an immunoglobulin or non-immunoglobulin protein.
- PEG may be linked to an oxidized carbohydrate residue (such method referred to as "gly- copegylation") on a protein molecule thereby minimizing the distortion of peptide portions of the protein that may be the result of pegylating amino acid primary amines.
- an oxidized carbohydrate residue may be formed by reacting a glycosylated (e.g. natively glycosylated) immunoglobulin molecule with a sugar oxidase enzyme.
- immunoglobulin-Gal-PEG conjugates may be synthesized by oxidizing a galactose (Gal) residue of an asialo- or desialylated Ig with galactose oxidase (GAO) , and then forming a Schiff base between the C6-aldehyde group of the Gal residue and an amino terminal group of Gly-PEG, with concurrent reductive alkylation of the imidic bond by reduction with pyridine borane (PB) .
- Gal galactose
- GEO galactose oxidase
- PB pyridine borane
- Section 8 infra provides a specific example of this method, in particular, the synthesis of human and mouse Ig conjugates with an amino acid derivative of PEG 3,400 (Gly-PEG).
- the present invention provides for a method of enhancing an immune response toward a heterologous peptide in a subject, comprising administering, to the subject, an effective amount of purified immunoglobulin molecule containing the heterologous peptide, wherein at least 5 percent of the lysine residues of the immunoglobulin molecule are covalently linked to polyethylene glycol.
- the pegylated immunoglobulins of the present invention may be useful in the diagnosis and treatment of a wide variety of malignancies and viral infections.
- the present invention provides for a method of treating a viral (or bacterial, proto ⁇ zoan, mycoplasmal, or fungal) infection comprising administering, to a subject in need of such treatment, an effective amount of a composition comprising pegy ⁇ lated immunoglobulin, as described in the preceding sections, containing a heterologous peptide which com ⁇ prises an epitope of a viral, bacterial, protozoan, mycoplasmal, or fungal antigen.
- treating refers to an amelioration in the clinical condition of the subject, and does not necessarily indicate that a complete cure has been achieved.
- An amelioration in clinical condition refers to a pro ⁇ longed survival, a decreased duration of illness, or a subjective improvement in the quality of life of the subject.
- the present invention provides for a method of enhancing an immune response directed toward a viral, protozoan, mycoplasmal, bacterial or fungal pathogen, in a subject in need of such treatment, com ⁇ prising administering, to a subject in need of such treatment, an effective amount of a composition comp ⁇ rising pegylated immunoglobulin, as described in the preceding sections, containing a heterologous peptide which comprises an epitope of a viral, protozoan, myco ⁇ plasmal, bacterial, or fungal antigen.
- enhancing an immune response refers to an increase in cellular and/or humoral immunity. In preferred embodi ⁇ ments, the amount of cellular and/or humoral immunity is increased in the subject by at least 25 percent. Such an enhanced immune response may be desirable during the course of infection, or before infection may have occurred (for example, in the context of a vac ⁇ cine) .
- the present invention also provides for a method of treating a malignancy or other neoplasm com ⁇ prising administering, to a subject in need of such treatment, an effective amount of a composition com ⁇ prising pegylated immunoglobulin, as described in the preceding sections, containing a heterologous peptide which comprises an epitope of an antigen associated with a malignancy or neoplasm.
- a composition com ⁇ prising pegylated immunoglobulin as described in the preceding sections, containing a heterologous peptide which comprises an epitope of an antigen associated with a malignancy or neoplasm.
- tumor regres ⁇ sion such as a decrease in tumor mass or in the number of metastases, of preferably at least 25 percent would be considered “treating”.
- the present invention provides for a method of enhancing an immune response directed toward a malignancy or other neoplasm, in a subject in need of such treatment, comprising administering, to a subject in need of such treatment, an effective amount of a composition comprising pegylated immunoglobulin, as described in the preceding sections, containing a heterologous peptide which comprises an epitope of an antigen associated with a malignancy or neoplasm.
- the effective amounts of the pegylated immunoglobulins of the invention may be determined empirically. Factors to be considered include the condition to be treated, whether or not the antibody will be complexed with or covalently attached to a toxin, route of administration for the composition, i.e. intravenous, intramuscular, subcutaneous, etc. , and the number of doses to be administered. Such factors are known in the art and it is well within the skill of physicians to make such determinations without undue experimentation.
- the pegylated immunoglobulins of the inven ⁇ tion offer a number of in vitro utilities, and the invention provides for methods based on such utilities.
- Such utilities include, for example, radioimmunoassays and ELISA assays, and fluorescence activated cell sorting.
- the half-life of non-immunoglobulin molecules may be extended by enzymatic pegylation of carbohydrate residues on the non-immunoglobulin molecules.
- the half-life of a viral protein may be extended by such pegylation, such that a vaccine comprising the viral protein may become more antigenic.
- an enzyme may be rendered more stable by such pegylation, so that the enzyme may be used more effectively in either enzyme supplementation therapy in vivo, or in diagnostic or therapeutic appli ⁇ cations.
- mice Six week old BALB/c mice were pur ⁇ chased from Jackson Laboratory (Bar Harbor, ME) .
- the synthetic peptide HA110-120 corresponds to amino acid residues 110-120 of the hemagglutinin (HA) of PR8 influenza A virus (Zaghouani et al., 1993, Science 259:224), NP 147-161 (TYQRTRALVRTGMDP; SEQ ID N0:16) corresponds to residues 147-161 of the nucleoprotein (NP) of PR8 influenza A virus (Zaghouani et al., 1992, J.Immunol., 148: 3604) and V 3 C peptide (RKSIHIGPGRAFYTTGEII; SEQ ID NO:l) corresponds to a consensus sequence predicted from the comparison of the V 3 cysteine bridged loop sequences of gpl20 envelope proteins of 245 HIV-1 isolates. Peptides were syn ⁇ thesized and RP-HPLC purified at IAF Biochem (Laval, Quebec, Canada) . KLH and BSA conjug
- Ig-HA and Ig-V 3 C are genetically engineered chimeric immunoglobulins.
- Ig-HA is a BALB/c IgG2b expressing, in the CDR3 loop, a T cell epitope (consisting of the HA110-120 peptide) from the HA of PR8 influenza A virus.
- Ig-NP is also a BALB/c IgG2b expressing, in the CDR3 loop, the NP147- 161 CTL-epitope consisting of the NP147-161 peptide.
- Ig-V 3 C is a chimeric immunoglobulin comprising mouse variable and human ⁇ l/k constant regions, and con ⁇ taining, within the heavy chain CDR3 loop, a B cell epitope from the V 3 cysteine bridged loop of the envelope protein of HIV-1.
- Ig-W is a chimeric immuno ⁇ globulin comprising wild type mouse V H and V L variable regions and human ⁇ l/k constant regions, which was used as a control for Ig-V 3 C.
- Ig-HA and Ig-NP were affinity purified from cell culture supernatant on a rat anti- mouse k chain-sepharose column.
- Ig-V 3 C and Ig-W were affinity purified on a mouse anti-human k chain anti ⁇ body (HP605)-sepharose column.
- PR8 influenza A virus was prepared from allantoic fluid of embryonated eggs on a sucrose gradient. An UV inactivated PR8 virus was used in these experiments.
- Ig- HA, Ig-NP, and Ig-V 3 C were derivatized with 2,4,6-trichloro-s-triazine activated mPEG 5,000 (Sigma) and purified to homogeneity. Briefly, a 50 times molar excess of mPEG was added to 10 mg of chimeric immuno ⁇ globulin in 10 ml of 0.1M tetraborate buffer, pH 9.6. The mixture was stirred vigorously for four hours at room temperature and the preparations were concentrated to 1.5 ml in CENTREX UF-2 ultraconcentrators of 100,000 MWCO (Schleicher & Schuell) .
- the residual unreacted mPEG was removed by size exclusion chromatography on an AcA44 Ultrogel column and homogeneous populations of Ig-mPEG with 6-8% derivatized lysines were isolated by anion exchange HPLC on Q300 column (for details of pro ⁇ cedure, see Example Section 7, below).
- the degree of mPEG derivatization was estimated by fluorescamine assay as described in Cunningham-Rundles et al., 1992, J.Immunol. Methods 152:177.
- Ig-HA-mPEG, Ig-V 3 C-mPEG conju ⁇ gates and native Ig-HA or Ig-V 3 C were dissolved in 25 ⁇ l of PBS and mixed with an equal volume of fresh fluorescamine in acetone (150 g/ml) . Samples were incubated for 5 min at room temperature and then adjusted to 1 ml with PBS. The absorbance was then measured at 475 nm emission versus 390 nm excitation and the percent of pegylated lysines was estimated according to the following formula: l-[(OD 475 Ig-mPEG / OD 475 native Ig)xl00]. The homogeneity of the conju ⁇ gates was confirmed by SDS-PAGE and agarose electro ⁇ phoresis.
- Ig-HA and Ig-HA-mPEG preparations (lOO ⁇ g in lOO ⁇ l of PBS) were radiolabeled with 125 I using the chloramine method and the free iodine was then removed by gel filtration on PD10 col ⁇ umns (Pharmacia) .
- Groups of three BALB/c mice were injected intravenously with 200 ⁇ l of PBS containing 20 x 10 6 cpm (4 ⁇ g) of 125 I-labeled native Ig-HA or Ig-HA- mPEG. Fifteen minutes later (time required for uniform distribution of labeled Ig) the mice were bled and the radioactivity in 20 ⁇ l of serum was counted.
- Organ distribution To study the tissue distribution of the native Ig-HA and Ig-HA-mPEG conjugates, two groups of seven mice each (15-17g weight) were injected intravenously with 200 ⁇ l PBS containing 20 x 10 6 cpm of 125 I-labeled native Ig-HA or Ig-HA-mPEG. Mice were bled after 15 min and the blood radioactivity was estimated as above. Fragments of liver, spleen, lung and kidney were then resected by 3, 6, 24, 48, 72, and 168 hours after inoculation and the radioactivity was measured in a ⁇ counter. Tissue distribution was expressed as index of distribution (%ID) of 125 I-Ig-HA or 125 1-Ig-HA-mPEG. ID represents the percentage of radioactivity per gram of wet organ versus the radioactivity measured in blood at 15 min after injection (Kitamura et al., 1990, Biochem. Biophys. Res. Commun.: 1387).
- mice immunized with Ig-HA or Ig-HA-mPEG were assessed for [ 3 H]-thymidine incorporation.
- the draining lymph nodes were collected and the cells were cultured in flat bottom 96-well microtiter plates (2 x 10 5 cells per well) with 0.5, 1, 5, and lO ⁇ g/ml of HA110-120, NP147-161, Ig-HA, Ig-NP, UV-inactivated PR8 virus, ConA (l ⁇ g/ml) or no antigen.
- Cultures were set up in quad ⁇ ruplets from pooled lymph node cells, incubated under standard conditions for 5 days (or 3 days in the case of ConA) , and pulsed for the last 18 hours with 1 ⁇ Ci of [ 3 H]-thymidine per well. The cells were then har ⁇ vested and the radioactivity was measured in a ⁇ scintillation counter. The mean of cpm obtained in the absence of antigen was subtracted from the mean of cpm obtained in the presence of antigens.
- Radioimmunoassay Detection of the anti-V 3 C peptide antibodies in mice sera was carried out by radioimmunoassay as follows: microtiter plates were coated with 50 ⁇ l of PBS containing 5 ⁇ g/ml of V 3 C pep ⁇ tide coupled to BSA (V 3 C-BSA) , BSA, or NP147-161-BSA for 18 hours at 40°C. The plates were extensively washed with PBS and then blocked with 3% BSA in PBS at room temperature. After 4 hours the plates were washed with PBS and serial serum dilutions (50 ⁇ l) in 1% BSA- PBS were added. The plates were incubated for 2 hours at 37°C.
- V 3 C-KLH con ⁇ jugate 100 ⁇ g
- V 3 C-KLH conjugate 50 ⁇ g
- IFA Incomplete Freund adjuvant
- mice sera Detection of anti-human isotypic antibodies in mice sera was carried out by radioimmunoassay as follows: microtiter plates were coated with 50 ⁇ l of PBS containing 2 ⁇ g/ml of Ig-W for 18 hours at 40°C. The plates were then treated as above. The amount of mouse anti-human Ig antibodies was estimated by extrapolation on a standard curve constructed with a stoichiometric mixture of mouse anti-human ⁇ l mAb (Zymed Laboratory) and HP6053 mouse anti-human kappa mAb (ATCC) . 6.2 . RESULTS
- Ig-HA and Ig-V 3 C were mildly pegylated and homogeneous conjugates with 6-8% mPEG substitution of the lysine residues were purified as described in Sec ⁇ tion 7, below.
- the conjugate preparations were rendered free of residual adducts such as free hydro ⁇ lyzed mPEG and highly conjugated or unconjugated immunoglobulin by size exclusion chromatography per ⁇ formed on AcA44 Ultrogel column followed by anion- exchange HPLC on Q300 column.
- the clearance rates of Ig ⁇ HA-mPEG from blood circulation were analyzed in paral ⁇ lel to those of native Ig-HA.
- 125 I-labeled Ig-HA-mPEG and Ig-HA were injected intravenously into BALB/c mice and the radioactivity was measured in blood samples collected at various intervals of time.
- native Ig-HA was cleared at 48 hours after injection while Ig-HA-mPEG persisted in peripheral blood up to 7 days.
- Ig-HA-mPEG showed a two phase clearance characterized by an initial rapid decline followed by a much slower decline.
- Serum samples from mice injected with 125 I-labeled native Ig- HA or Ig-HA-mPEG were collected at various intervals of time and analyzed by Western blot analysis. Both native and pegylated Ig-HA showed significant degrada ⁇ tion between 6 and 24 hours after injection. By 48 hours, the majority of the proteolytic products were cleared from the blood, and by 72 hours intact immuno ⁇ globulin molecules were detected only in samples from mice injected with Ig-HA-mPEG ( Figure 2) .
- Tissue distribution We carried out kinetic studies to estimate the amount of radioactivity in various tissues at various intervals of time after injection of the radiolabeled conjugates.
- the tissue distribution of 125 I-Ig-HA and 125 1-Ig-HA-mPEG was studied in liver, spleen, lung and kidney resected at 0.25, 3, 6, 24, 48, 72 and 168 hours after injection. As illustrated in Figure 3, both Ig-HA and Ig-HA-mPEG were taken up by the various organs to the same extent but the amounts of Ig-HA-mPEG retained in the organs were higher than those of native Ig-HA.
- Ig- V 3 C is a chimeric molecule made up of murine V H gene expressing the consensus V 3 C peptide, murine V k gene and human ⁇ l and constant region genes. Therefore, we measured by RIA the antibody response against the V 3 C epitope as well as against isotypic determinants of human constant regions.
- EXAMPLE PURIFICATION OF PEGYLATED IMMUNOGLOBULIN
- various degrees of derivatization may occur as a consequence of the micro heterogeneity of the protein, the distri ⁇ bution of both the number and the position of attach ⁇ ment of PEG units, the inherent polydispersity of PEG polymers, and microenvironmental conditions of the reaction.
- deoxy PEG that can crosslink proteins may be present in commercial preparations as a result of hydrolysis of the ethylene oxide monomers during the polymerization process (Selisko et al., 1993, J. Chromatogr.
- protein-mPEG preparations may contain species of highly pegylated and/or cross ⁇ linked proteins in addition to the residual adducts. Purification of homogeneous populations of conjugates is therefore required prior to their use in biological systems. Purification of protein-PEG conjugates has generally consisted of a single step chromatographic removal of free PEG polymers (Kitamura, et al., 1991 Cancer Res., 51: 4310-43115; Cunningham-R.A.et al., 1992, J.
- AIgs Ig-HA and Ig-V 3 C
- PhastSystem electrophoresis apparatus PhastGels 4-15% gradient of polyacrylamide and cyanogen bromide activa ⁇ ted Sepharose CL-4B were purchased from Pharmacia, LKB.
- AcA44 Ultrogel and dialysis bags of 75,000 MWCO were from Spectrum, Co.
- Ultra concentrators of 100,000 MWCO (CENTREX UF-2, 2ml volume) were from Schleicher & Schuell.
- Rat hybridoma cells secreting monoclonal anti-murine k chain antibodies and HP6053 mouse hybri ⁇ doma producing anti-human k chain antibodies were from ATCC.
- the Q300 HPLC column 250 x 4.6 mm, 300 micron particle size) was from Rainin.
- Nessler reagent and 2,4,6-trichloro-s-triazine activated monomethoxypoly- ethylene glycol MW 5,000 (mPEG 5,000) were from Sigma.
- the agarose gels (Titan Gel High-Resolution Protein kit) were from Helena Laboratories.
- AIgs Purification of AIgs.
- IgHA and Ig-V 3 C were affinity purified on a rat anti-murine k chain and mouse anti-human k chain antibody-Sepharose columns, respectively.
- Affinity purified AIgs were equilibrated in 0.IM sodium tetraborate, pH 9.6 and concentrated to 1 mg/ml by ultracentrifugation using tubes of 100,000 MWCO.
- Alg-mPEG conjugates Chromatographic purification of Alg-mPEG conjugates.
- Alg-mPEG preparations were applied to a AcA44 Ultrogel filtration column (80 x 1.6cm) equili ⁇ brated with 0.1M NH 4 HC0 3 , pH 8.5 and flow rate of 0.4 ml/min. Fractions were collected at 4 min interval, dried by speed vacuum centrifugation and resuspended in 0.5 ml of 5mM sodium-acetate, pH 5. Each fraction was then analyzed for protein content by Biuret micro assay, and for the presence of free hydrolyzed mPEG by Nessler's reagent as described in Wilkinson et al., 1987, Immunol.Lett.
- Figure 7 shows the elution profiles of Ig-HA-mPEG ( Figure 7A) and free IG-HA ( Figure 7b) .
- Ig-HA-mPEG 3 major peaks were eluted from the column and labeled 1, 2, and 3 ( Figure 7a).
- Peak 3 represents free Ig-HA since it elutes at the same salt concentration as the unconjugated control Ig-HA.
- the material of peak 1 may represent highly pegylated AIgs that could not bind to the matrix.
- Peak 2 contained mildly pegylated Ig-HA as revealed by SDS-PAGE analysis (see below) .
- Alg-mPEG conjugates Analysis of the homogeneity of Alg-mPEG conjugates.
- the purity of Algs-mPEG preparations was further analyzed for the presence of traces of free mPEG and residual adducts performed on agarose and polyacrylamide gel electrophoresis, respectively.
- purification of Algs-mPEG conjugates followed one step purification by size exclusion chromatography, small amounts of free mPEG that could not be detected by Nessler's test may be present in the conjugate preparations.
- To trace small amounts of free PEG that could interfere with the immunogenicity of the Algs- mPEG we developed an original, sensitive electro- phoretic technique able to detect ⁇ M of free mPEG.
- the amount of free resi ⁇ dual mPEG, if any, in the final Ig-HA-mPEG preparation should be lower than 4 x 10 ⁇ 4 M.
- a duplicate gel was stained with Coomas- sie/Ponceau (Fig. 8, right panel), only Ig-HA and Ig ⁇ HA-mPEG conjugates were revealed (lanes 1, 2, respect ⁇ ively) but not free hydrolyzed mPEG (lane 3) .
- Inter ⁇ estingly, pegylated Ig-HA showed better staining with Ponceau S than unpegylated Ig-HA.
- the differential staining may be attributed to different ability of the two dyes to access their specific sites on the native protein versus the pegylated one.
- immunoglobulins have been found to exhibit a remarkable increase in half-life when 6 - 8% of the primary amines are chemically conjugated to mPEG 5,000.
- mild pegylation may preserve the immunogenicity of hidden determinants on immuno ⁇ globulins
- higher degrees of pegylation may produce undesirable tolerogenic and/or suppressogenic effects for foreign epitopes present on immunoglobulins used for immunization purposes.
- Tolerization of an immuno ⁇ genic epitope may occur as a consequence of PEG attach ⁇ ment to the particular epitope.
- pegylation of a CDR may destroy the functional activity of the CDR.
- PEG has been targeted to carbohydrate moieties found on immunoglobulin molecules in order to increase the half- life of the immunoglobulins while preserving their bio ⁇ logical activity.
- Ig-HA is a BALB/c IgG2b comprising, in the CDR3 loop, a T cell epitope (HA110-120) from the hemagglutinin (HA) of PR8 influenza A virus.
- igW is a BALB/c IgG2b com ⁇ prising the unmutated V H region of the anti-arsonate 91A3 mAb.
- Ig-TB is an Ig-HA chimera in which a HA150- 163 B cell epitope was genetically engineered into the CDR2 loop.
- size exclusion chromatography on Superose-6 column was performed as described below.
- Rat anti- mouse K chain mAb was purified from cell culture super- natant by affinity chromatography on a mouse anti-rat (MAR 18.5) sepharose column.
- the genetically engineered chimeras were purified from cell culture supematants by affinity chromatography on rat anti- mouse k chain-sepharose column.
- Rat anti-mouse k chain mAb (lmg) was first desialylated with a mixture of neuraminidases (50 mU, 1:1) from Arthrobacter ureafaciens (90.8 U/mg pro ⁇ tein) , and Clostridium perfringens (4.8 U/mg protein, Calbiochem) by incubating the reaction mixture over ⁇ night at 37°C with 1ml of phosphate buffer, pH 6 con ⁇ taining 5 mM of CaCl 2 . The kinetics of the desialyl- ation reaction may be monitored by determining free NANA released in solution, as described in Warren, 1959, J. Biol. Chem. 234:1971.
- Ig-Gal- PEG conjugates were concentrated by speed vacuum cen ⁇ trifugation and applied to a Superose-6 HR10/30 column (Pharmacia, LKB) equilibrated in PBS at a flow rate of 0.2 ml/min. Fractions were collected every minute and the tubes containing the conjugates were pooled and tested for protein concentration by Biuret micro-assay and for the presence of free PEG using methods set forth in the preceding sections. The chromatographic profiles were monitored at the maximum absorbance for PEG (254nm) . Ig-Gal-PEG conjugates were concentrated and used for further investigations.
- the Ig-Gal-PEG conjugates were analyzed in comparison with native Igs (20 ⁇ g in lO ⁇ l) by isoelectric focusing. Electro ⁇ phoresis was carried out in 5% polyacrylamide gels (PAG plate, pH 3-10 Pharmacia, LKB) for 90 min at 15°C and 1500 Volts, 50 Watts and 30 mAmps. Gels were stained with Coomassie and photographed ( Figure 13) . The pi values were determined on a pi standard curve con ⁇ structed with a broad pi range standards (Pharmacia, LKB) .
- a reaction mixture containing either 0.5 mg immuno ⁇ globulin (e.g., human IgA, rat anti-mouse k chain mAb, mouse IgGl B43.13 mAb), or graded amounts of D- galactose (0.019 to 5 ⁇ g) was mixed with 30 U horse ⁇ radish peroxidase, 0.5 mg tilidine and 2.5 U GAO in 0.IM sodium phosphate at pH 7.
- the mixture was incu ⁇ bated for 18 h at 37°C and the absorbance was deter ⁇ mined at 425 nm.
- a calibration curve using D-galactose was used to determine the relative "galactose equivalents" on native Igs.
- Mouse IgGl B43.13 mAb has been used in reaction as a known Ig containing 6.3 nM of galactose residues which corresponds to 4 Gals but showing only 2.1 nM reactive galactose residues (1 residue) .
- the results of these studies were that the potential galactose sites available for coupling to PEG were four for the rat IgG2b anti-mouse k chain MAB and eight for human IgA from colostrum.
- a reaction mixture made of GAO (2.5 U) , D-galactose (1 ⁇ g) , 30 U horse ⁇ radish peroxidase, 0.5 mg tilidine and 80mM of pyridine borane (PB) in 0.1M sodium phosphate at pH 7 was incu ⁇ bated for 18 h at 37°C and the absorbance was deter ⁇ mined at 425 nm.
- the same reaction mixture was tested in the presence of graded amounts of Gly-PEG 3,500 corresponding to similar GAO/Gly-PEG molar ratios that may be used in the coupling reaction of Igs with Gly- PEG 3,500 (Figure 16). The results of these studies were that slightly increased GAO activity was observed when PEG was co-incubated in the reaction mixture.
- ORGANISM Human Immunodeficiency Virus Type 1
- ORGANISM Measles Virus
- ORGANISM Foot and Mouth Disease Virus
- ORGANISM Streptococcus A
- ORGANISM Staphylococcus sp.
- MOLECULE TYPE peptide
- ORIGINAL SOURCE (A) ORGANISM:
Abstract
The present invention relates to pegylated proteins, including modified immunoglobulin molecules mildly derivatized with polyethylene glycol. Such 'pegylated' immunoglobulins may be used to produce an enhanced immune response in the absence of adjuvant. In particular embodiments, the present invention relates to proteins conjugated to polyethylene glycol via carbohydrate residues.
Description
Description
PEGYLATED MODIFIED PROTEINS 1. INTRODUCTION
The present invention relates to pegylated proteins, including modified immunoglobulin molecules mildly derivatized with polyethylene glycol. Such "pegylated" immunoglobulins may be used to produce an enhanced immune response in the absence of adjuvant. In particular embodiments, the present invention relates to proteins conjugated to polyethylene glycol via carbohydrate residues.
2. BACKGROUND OF THE INVENTION
Polyethylene glycol ("PEG") is non-toxic, non-immunogenic, and is approved by the United States Food and Drug Administration for internal use in humans. It has been reported that covalent binding of monomethoxypolyethylene glycol ("mPEG") to proteins improves their solubility and half-life without sig¬ nificantly altering their biologic activity (Katre et al., 1987, Proc. Natl. Acad. Sci. U.S.A. 84_:1487; Suzuki et al., 1984, Biochim. Biophys. Acta 788;248; Kitamura et al., 1990, Biochem. Biophy. Res. Commun. 2:1387; Kitamura et al., 1991, Cancer Res. .51: 4310). For example, bovine serum catalase mildly derivatized with mPEG was found to retain full enzymatic activity in vitro (Abuchows i et al., 1977, J. Biol. Chem. 252:3582) . Thereafter, various enzymes derivatized with mPEG were used for enzyme substitution and cancer therapy (Abuchowski et al. , 1984, Cancer Biochem. Biophys. 2:175). Proteins of therapeutic use such as recombinant interleukin 2 ("rIL-2") were also derivatized with mPEG and showed increased potency to stimulate specific CTL activity in a murine sarcoma model (Katre et al., 1987, Proc. Natl. Acad. Sci. U.S.A. *-1487).
Mild conjugation to PEG ("pegylation") was used to increase the half-life of tumor-specific intact immunoglobulin molecules and F(ab,)2 fragments without significant alteration of the binding capacity to tumor antigens (Kitamura et al., 1990, Biochem. Biophy. Res. Commun. 2:1387). Pegylated anti-tumor antibodies were able to enhance tumor localization (Kitamura et al., 1991, Cancer Res. £>1: 4310) . However, tolerance to xenogeneic immunoglobulin determinants was achieved when the immunoglobulins were heavily derivatized with mPEG 5000 (Wilkinson et al., 1987, J. Immunol. 139:326) . Furthermore, it was shown that synthetic self-peptides derivatized with mPEG were able to sup¬ press the production of autoantibodies to acetylcholine receptor and to prevent experimental myasthenia gravis in mice (Atassi et al., 1992, Proc. Natl. Acad. Sci. U.S.A. 89:5852) .
The increase in half-life of pegylated immuno¬ globulins was correlated with resistance to proteolytic enzymes and with low clearance rate through the kidney. Indeed, when seven percent of the primary amines of human immunoglobulin were substituted with mPEG, the conjugates were resistant to trypsin digestion, and at 14 percent substitution they were resistant to pepsin digestion (Cunningham-Ruddles et al., J. Immunol. Methods 152:177) . This indicated that pegylated immuno¬ globulin may be used in oral administration in the treatment of some gastrointestinal diseases.
3. SUMMARY OF THE INVENTION The present invention relates to proteins which are covalently conjugated to polyethylene glycol ("pegylated") . In a first set of embodiments, the pre¬ sent invention provides for pegylated immunoglobulins. For example, immunoglobulin containing an immunogenic heterologous peptide corresponding to a T cell or a B
cell epitope may be pegylated to increase the half-life of the immunoglobulin without substantially decreasing the biological activity of the immunoglobulin molecule or the immunogenicity of the heterologous peptide. Such pegylated immunoglobulins containing heterologous peptide may be used to produce an enhanced immune response to the heterologous peptide in a subject. Such pegylated immunoglobulins may also be used to elicit an immune response to the heterologous peptide in a subject in the absence of adjuvant.
In further embodiments, the present invention provides for proteins that are conjugated to poly¬ ethylene glycol via carbohydrate residues, and for methods of producing such "glycopegylated" proteins. Proteins which may be pegylated in this manner include, but are not limited to, immunoglobulin, antigenic pro¬ teins, therapeutic proteins, and proteins used for diagnostic purposes.
4. DESCRIPTION OF THE FIGURES Figure 1. Blood clearance of native and pegylated Ig-HA. Mice (three per group) were injected intravenously with 125I-labeled Ig-HA or Ig-HA-mPEG. The mice were rested for 15 minutes to allow uniform distribution of radiolabeled material and then blood samples were collected at various intervals of time. Radioactivity content of total blood volume was estimated and considered as the total radioactivity injected (TRI) . Blood samples were collected at indi¬ cated times and total residual radioactivity (TRR) was estimated. The percent of residual activity was esti¬ mated according to the following formula [1-(TRR/TRI) ] x 100. Each point represents the mean ± SD of three mice.
Figure 2. In vivo proteolysis of native and pegylated Ig-HA. Serum samples from mice injected
intravenously with 125I-labeled Ig-HA or Ig-HA-mPEG (20 x 106 cpm/mouse) were collected at indicated times after injection and 5/xl of serum was run on an 8-17% gradient polyacrylamide gel. Separated material was electrotransferred onto PVDF membranes and exposed to Kodak X-OMAT films. The left panel (A) shows the pat¬ tern of in vivo degradation, over time, of samples collected from a mouse injected with Ig-HA. The right panel (B) shows the pattern of in vivo degradation, from a mouse injected with Ig-HA-mPEG. Samples of 125I labeled Ig-HA and Ig-HA-mPEG (5 x 104 cpm/5μl) were analyzed in parallel in the corresponding panel and used as controls (C) of non- degraded material prior to inoculation into mice.
Figure 3. Tissue distribution of native and pegylated Ig-HA. Groups of seven mice each (15-17 g weight) were injected intravenously with 125I-labeled Ig-HA or Ig-HA-mPEG. The mice were rested for 15 min to allow uniform distribution of the labeled material and blood samples were collected. Fragments of vis¬ ceral organs (liver (A) ; spleen (B) ; Kidney (C) ; lung (D)) were then resected at indicated times after injec¬ tion. The tissue distribution of native or pegylated Ig-HA was estimated as index of distribution (% ID) . Each point represents % ID for a mouse corresponding to the indicated time after injection.
Figure 4. I__ vitro activation of HA110-120 specific LDl-24 T cell hybridomas by native and pegy¬ lated Ig-HA. Graded amounts of chromatographically purified Ig-HA, Ig-HA-mPEG and Ig-NP-mPEG were incu¬ bated with 2PK3 antigen presenting cells ("APCs"; 104) and LDl-24 T hybridoma cells (2 x 104) . Activation of LDl-24 T cells was assessed 48 hours later by measuring IL-3 production in the cell supernatant using IL-3 dependent DA-1 cells (15 x 104) and MTT assay. Each
point represents the mean of quadruplets plus or minus SD.
Figure 5. Iτι vivo priming of HA110-120 specific T cells by native and pegylated Ig-HA. Four groups of seven mice each were immunized subcutaneously at the base of the tail and in the foot pads with Ig-HA or IgHA-mPEG in either saline or CFA. Ten days later the draining lymph nodes were collected and cells were cultured for 5 days in standard conditions with graded amounts of various antigens. [3H]-thymidine was added for 18 hours and incorporation was measured. Panels (a) and (b) represent the [3H]-thymidine incorporation by lymph node cells from mice immunized with Ig-HA in saline and CFA, respectively. Panels (c) and (d) represent the [3H]-thymidine incorporation by lymph node cells from mice immunized with Ig-HA-mPEG in saline and CFA, respectively. In all cases stimulation in vitro was carried out with graded amounts (0.5, 1, 5 and lOμg/ml) of Ig-HA, Ig-NP, HA110-120 synthetic pep¬ tide, NP147-161 synthetic peptide or UV-inactivated PR8 virus. [3H]-thymidine incorporation upon in vitro stimulation with concanavalin A ("ConA") for three days is also indicated. Each point represents the mean of quadruplet wells plus or minus SD, after subtraction of cpm obtained in the absence of antigen.
Figure 6. AntiJody response of mice immunized with native and pegylated Ig-V3C. Groups of three mice were immunized with either Ig-V3C (open circles) or Ig-V3C-mPEG closed circles) , bled at indi¬ cated intervals of time and the titers of antibodies to V3C peptide (panels a, b, c and d) and to human iso- typic determinants (panels e, f, g and h) were deter¬ mined. In panel a and c the mice were immunized sub¬ cutaneously with lOOμg of either Ig-V3C or Ig-V3C-mPEG emulsified in CFA and boosted two weeks later with 50μg of antigens in Incomplete Freund's adjuvant (IFA) .
Arrows indicate the days of immunization. The other protocols of immunizations were performed with either three injections i.p. of lOOμg of antigen in saline at seven day intervals (panels b and f) , or two injections intraperitoneally of lOOμg of antigens in saline at seven day intervals (panels c and g) , or a single injection intraperitoneally of lOOμg of antigens in saline (panels d and h) . The antibody titers were determined by RIA. Each point represents the mean plus or minus S.D. of three mice.
Figure 7. Separation of Ig-HA-mPEG conjugates from unpegylated Ig-HA by HPLC on Q300 anion exchange column . Panel (a) shows the elution profile of the material collected from peak 1 in Figure 10 and loaded onto the Q300 column. Panel (b) shows a control elution profile of a preparation of unpegylated Ig-HA.
Figure 8. Detection of residual mPEG in Algs- mPEG preparations by electrophoresis on Titan agarose Gel. Samples collected at various steps of purification were run on duplicate Titan gels and either stained with Coomassie/Ponceau (R250) or precipitated with TCA. Lane 1, IgHA-mPEG conjugate after purification on anion-exchange HPLC; lane 2, unpegylated IgHA; lane 3, mPEG 5,000 (4 x 10"M) ; lane 4, IgHA-mPEG conjugate after first step of purification by gel filtration on AcA44 (not done in Coomassie staining) .
Figure 9. Analysis of homogeneity of Alg-mPEG preparations by SDS-PAGE. Samples collected subsequent to purification on anion-exchange HPLC were analyzed on 4-15% polyacrylamide gradient PhastGels (Pharmacia) under nonreducing conditions. Lanes l and 4, unpegy¬ lated Ig-HA and Ig-V3C, respectively; lanes 2 and 4, Ig-HA-mPEG and Ig-V3C-mPEG, respectively (content of peak 2 in Figure 8) ; and lanes 3 and 6 highly derivatized Ig-HA and Ig-V3C (content of peak l in Figure 8) .
Figure 10. Removal of hydrolyzed mPEG from Alg-mPEG preparation by size exclusion chromatography. AcA44 Ultrogel column (80 x 1.6 cm) was calibrated at 0.4 ml/min flow rate with molecular weight markers (Pharmacia, LKB) and then loaded with 10 mg of IgHA- mPEG preparation. The column was equilibrated with either 0.1M NH4HC03 (panel a) or PBS (panel b) . The peak labeled 1 contained the conjugates and peak 2 corresponds to free mPEG. A plus sign indicates the presence of free polymer as detected by Nessler's test.
Figure 11. Diagram of synthesis of Ig-Gal- PEG conjugates.
Figure 12. SDS-PAGE Analysis of Ig-Gal-PEG Conjugates. Chromatographic purified samples of the Ig-gal-PEG conjugates were analyzed on 4-20% poly¬ acrylamide gradient gels under reducing and non- reducing conditions and stained with Coomassie R-250. Lanes 1 and 2 show reduced unpegylated and reduced pegylated human IgA from colostrum.
Figure 13. Isoelectric Focusing of Ig-Gal- PEG Conjugates. Chromatographic purified samples of the Ig-Gal-PEG conjugates were analyzed on PAG plates with a pH gradient between 3 and 10, as described in Section 8. Lane l shows the pi markers, pH 3-10, and lanes 2 and 3, pegylated and unpegylated human IgA from colostrum, respectively.
Figure 14. Titan Gel Electrophoresis of Ig- Gal-PEG Conjugates. Ig-Gal-PEG conjugates were anal¬ yzed by agarose electrophoresis as described in Section 8. Lane 1 represents glycopegylated human IgA and lane 2 represents native human IgA.
Figure 15. Estimation of "Gal Equivalents" on Native Igs. The Gal residues of human IgA from colostrum and rat IgG2b anti-mouse k chain mAb were determined by measuring GAO enzymatic activity as com¬ pared to known amounts of D-galactose, as described in
Section 8. Dotted plot represents GAO activity on D- galactose as a substrate. The corresponding Gal resi¬ dues per molecule of Ig (nMole/Ig molecule) were cal¬ culated according to data obtained from GAO activity on the monosaccharide substrate (lower side of the abscissa) . These data were then translated in number of "galactose equivalents" (upper side of the abscissa), knowing that 2.1 to 2.3 nMole of Gal resi¬ dues corresponds to one Gal residue per molecule of Ig. As the rectangles indicate, the potential galactose sites of Igs for coupling to Gly-PEG were approximately four for the rat IgG2b anti-mouse k chain mAb and eight in the case of human IgA from colostrum.
Figure 16. Estimation of GAO Activity in the Presence of PEG. GAO activity was tested in the pres¬ ence of different amounts of Gly-PEG 3,500 as described in Section 8. Slightly increased GAO activity was observed when PEG was co-incubated in the reaction mix¬ ture for 18 h at 37°C.
5. DETAILED DESCRIPTION OF THE INVENTION For purposes of clarity, and not by way of limitation, the detailed description of the invention is divided into the following subsections: (i) immunoglobulin molecules; (ii) non-immunoglobulin molecules; (iii) pegylation methods; and
(iv) utilities of the invention. 5.1. IMMUNOGLOBULIN MOLECULES In a first set of embodiments, the present invention relates to immunoglobulin molecules modified to contain a heterologous peptide, which are covalently conjugated to polyethylene glycol ("pegylated"). The heterologous peptide may be an immunogenic peptide or other biolocially active peptide.
The term "immunogenic", as used herein, is construed to mean that the heterologous peptide occur¬ ring in the modified immunoglobulin molecule is capable of eliciting a specific immune response. Preferably, the immunogenic heterologous peptide is a B cell epi¬ tope or a T cell epitope.
The invention is based, at least in part, on the discovery that the stability of such immuno¬ globulins and/or their ability to enhance the immune response is augmented when the modified immunoglobulins are mildly derivatized with polyethylene glycol ("pegy¬ lated") .
For example, mild derivatization of the immunoglobulins containing a B cell or a T cell epitope may significantly increase the half-life of the immuno¬ globulin molecules without substantially decreasing the biological activity of the immunoglobulin molecule or the immunogenicity of the heterologous peptide. As used herein, "a substantial decrease" of the biological activity of an immunoglobulin molecule refers to the situation where the biological activity of the immuno¬ globulin has decreased to an extent where the immuno¬ globulin loses its ability to effectively deliver the B cell or a T cell epitope to immune cells. A "substan¬ tial decrease" in the immunogenicity of a B cell or a T cell epitope refers to the effective inability of the epitope to elicit a specific immune response.
Mild pegylation of immunoglobulin molecules containing a B cell epitope or a T cell epitope enhances the immunogenicity of the epitope and may obviate the requirement for adjuvants. For example, and not by way of limitation, the beneficial effects of pegylation of various immunoglobulins is set forth in Example Sections 6 and 7, below.
The present invention further provides for a method of pegylation which conjugates PEG to carbo-
hydrate residues of an immunoglobulin molecule, thereby minimizing structural distortion of the peptide back¬ bone of the immunoglobulin or any heterologous epitopes comprised therein. A working example of such "glyco- pegylation" is set forth in Example Section 8, below.
The present invention may be applied to any immunoglobulin molecule, including human and nonhuman immunoglobulin molecules, immunoglobulin molecules con¬ taining both human and nonhuman portions, and immuno¬ globulins of any class (e.g. IgG, IgM, IgD, IgE, or IgA) and any specificity.
Such immunoglobulin molecules are modified to contain a heterologous peptide. For example, such a heterologous peptide may be a B-cell or T-cell epitope of an antigen, a cytokine, a toxin, or an idiotypic determinant, which has been covalently linked to the immunoglobulin molecule.
Such covalent linkage may be accomplished by genetic engineering techniques in which a nucleic acid sequence encoding the heterologous peptide is inserted into a nucleic acid sequence encoding the immuno¬ globulin molecule. Most preferably, the nucleic acid sequence encoding the heterologous peptide replaces a similarly sized sequence of a complementarity deter¬ mining region ("CDR") of the immunoglobulin molecule, as set forth in United States patent application Serial No. 08/363,276. The engineered nucleic acid may then be incorporated into a suitable expression vector and expressed as a protein comprising an immunoglobulin molecule covalently linked to the heterologous peptide. More than one heterologous peptide (of the same or dif¬ ferent variety) may be incorporated into the immuno¬ globulin by this method.
In one example, the genetically engineered immunoglobulin molecule contains a heterologous pep¬ tide, such as a T cell or a B cell epitope, in place of
a CDR loop of the immunoglobulin molecule, the CDR loop having been deleted and replaced with the heterogenous peptide. The CDR loop that is deleted and replaced with the heterologous peptide may be located in either the heavy or the light chain and may be CDR1, CDR2, or CDR3 loop.
The genetically engineered immunoglobulin molecule containing a heterologous peptide may be, for example, a humanized immunoglobulin molecule, an exam¬ ple of which is an immunoglobulin molecule genetically engineered to comprise the constant regions of a human immunoglobulin and the variable regions of a murine immunoglobulin.
Alternatively, the heterologous peptide may be linked to the immunoglobulin molecule by enzymatic means. For example, and not by way of limitation, the heterologous peptide may be linked to the immuno¬ globulin molecule via a carbohydrate residue of the immunoglobulin molecule, as set forth in United States Patent Application Serial No. 08/441,328, using a method analogous to the linkage of PEG to enzymatically oxidized carbohydrate residues of an immunoglobulin molecule, as exemplified in Section 8, below. In a preferred specific embodiment, heterologous peptide may be conjugated to enzymatically oxidized carbohydrate groups (e.g. galactose residues oxidized by galactose oxidase enzyme) by Schiff base formation, followed by reduction (e.g. with pyridine borane) . Multiple heterologous peptides (of the same or different variety) may be linked to the immunoglobulin molecule by this method.
Virtually any peptide may be used according to the invention. Such peptides may comprise at least 2 and preferably at least five amino acid residues and may comprise immunogenic epitopes of antigens; suitable antigens include, but are not limited to, antigens
associated with pathogens, tumor cells, or "non-self" antigens with respect to a particular individual. Peptides may be biologically active themselves (for example, growth factors, toxins, immune mediators, differentiation factors etc.) or be portions of bio¬ logically active proteins. In specific, nonlimiting examples, the peptide may comprise all, or a portion, of IL-1 or tetanus toxoid.
In non-limiting embodiments, peptides which may be used according to the invention include B cell epitopes. The term "B cell epitope", as used herein, refers to a peptide, including a peptide comprised in a larger protein, which is able to bind to an immuno¬ globulin receptor of a B cell and participate in the induction of antibody production by the B cell.
For example, and not by way of limitation, the hypervariable region 3 loop ("V3 loop") of the envelope protein of human immunodeficiency virus ("HIV") type 1 is known to be a B cell epitope. Although the sequence of this epitope varies, the following consensus sequence, corresponding to residues 301-319 of HIV-1 gpl20 protein, has been obtained: Arg- Lys-Ser-Ile-His-Ile-Gly-Pro-Gly-Arg-Ala-Phe-Tyr-Thr- Thr-Gly-Glu-Ile-Ile (SEQ ID N0:1).
Other examples of known B cell epitopes which may be used according to the invention include, but are not limited to, epitopes associated with influenza virus strains, such as Trp-Leu-Thr-Lys-Lys-Gly-Asp-Ser- Tyr-Pro (SEQ ID NO:2), which has been shown to be an immunodominant B cell epitope in site B of influenza HA1 hemagglutinin, the epitope Trp-Leu-Thr-Lys-Ser-Gly- Ser-Thr-Tyr-Pro (H3; SEQ ID NO:3), and the epitope Trp-Leu-Thr-Lys-Glu-Gly-Ser-Asp-Tyr-Pro (H2; SEQ ID NO:4; Li et al., 1992, J. Virol. 16:399-404); an epitope of F protein of measles virus (residues 404- 414; Ile-Asn-Gln-Asp-Pro-Asp-Lys-Ile-Leu-Thr-Tyr; SEQ
ID NO:5) Parlidos et al., 1992, Eur. J. Immunol. 22.:2675-2680) ; an epitope of hepatitis virus pre-Sl region, from residues 132-145 (Leclerc, 1991, J. Immunol. 147:3545-3552) ; and an epitope of foot and mouth disease VP1 protein, residues 141-160, Met-Asn- Ser-Ala-Pro-Asn-Leu-Arg-Gly-Asp-Leu-Gln-Lys-Val-Ala- Arg-Thr-Leu-Pro (SEQ ID NO:6; Clarke et al., 1987, Nature 330:381-384) .
Still further B cell epitopes which may be used are known or may be identified by methods known in the art, as set forth in Caton et al., 1982, Cell 21:417-427.
In additional embodiments of the invention, peptides which may be used may be T cell epitopes. The term "T cell epitope", as used herein, refers to a pep¬ tide, including a peptide comprised in a larger pro¬ tein, which may be associated with MHC self antigens and recognized by a T cell, thereby functionally activating the T cell.
For example, a peptide may comprise a Th epi¬ tope, which, in the context of MHC class II self anti¬ gens, may be recognized by a helper T cell and thereby promote the facilitation of B cell antibody production via the Th cell.
For example, and not by way of limitation, influenza A hemagglutinin (HA) protein bears, at amino acid residues 110-120, a Th epitope having the amino acid sequence Ser-Phe-Glu-Arg-Phe-Glu-Ile-Phe-Pro-Lys- Glu (SEQ ID NO:7) .
Other examples of known T cell epitopes include, but are not limited to, two promiscuous epi¬ topes of tetanus toxoid, Asn-Ser-Val-Asp-Asp-Ala-Leu- Ile-Asn-Ser-Thr-Lys-Ile-Tyr-Ser-Tyr-Phe-Pro-Ser-Val (SEQ ID NO:8) and Pro-Glu-Ile-Asn-Gly-Lys-Ala-Ile-His- Leu-Val-Asn-Asn-Glu-Ser-Ser-Glu (SEQ ID NO:9; Ho et al., 1990, Eur. J. Immunol. 2I:477-483) ; an epitope of
cytochrome c, from residues 88-103, Ala-Asn-Glu-Arg- Ala-Asp-Leu-Ile-Ala-Tyr-Leu-Gln-Ala-Thr-Lys (SEQ ID NO:10); an epitope of Mycobacteria heatshock protein, residues 350-369, Asp-Gln-Val-His-Phe-Gln-Pro-Leu-Pro- Pro-Ala-Val-Val-Lys-Leu-Ser-Asp-Ala-Leu-Ile (SEQ ID NO:ll; Vordermir et al., Eur. J. Immunol. 24:2061- 2067) ; an epitope of hen egg white lysozyme, residues 48-61, Asp-Gly-Ser-Thr-Asp-Tyr-Gly-Ile-Leu-Gln-Ile-Asn- Ser-Arg (SEQ ID NO:12; Neilson et al., 1992, Proc. Natl. Acad. Sci. U.S.A. £:7380-7383) ; an epitope of Streptococcus A M protein, residues 308-319, Gln-Val- Glu-Lys-Ala-Leu-Glu-Glu-Ala-Asn-Ser-Lys (SEQ ID NO:13; Rossiter et al., 1994, Eur. J. Immunol. 24.:1244-1247) ; and an epitope of Staphylococcus nuclease protein, residues 81-100, Arg-Thr-Asp-Lys-Tyr-Gly-Arg-Gly-Leu- Ala-Tyr-Ile-Tyr-Ala-Asp-Gly-Lys-Met-Val-Asn (SEQ ID N0:14; de Magistris, 1992, Cell £8:1-20). Still fur¬ ther Th epitopes which may be used are known or may be identified by methods known in the art.
If the peptide comprises a T cell epitope, it may be desirable to provide a means for releasing the T cell epitope from the immunoglobulin so as to facil¬ itate appropriate processing by an antigen presenting cell ("APC") . For example, it may be desirable to incorporate the T cell epitope into a larger peptide which comprises a site susceptible to cleavage by an enzyme typically present in lysosomes of APCs. As a specific example, the lipophilic quadruplet Ala-Ala- Ala-Leu (SEQ ID NO:15), that contains the cleavage site for cathepsins (Yonezawa et al., 1987, Arch. Biochem. Biophys 256:499) . may be added to the T cell epitope. It is known that lysosomal cathepsins play an important role in processing of exogenous molecules.
Peptides for use according to the invention may be purified from natural sources, or may be recom- binantly and/or chemically synthesized. They may con-
tain amino acid analogs, and may be detectably label¬ led.
Immunoglobulins may be covalently linked to polyethylene glycol ("pegylated") by any method known in the art for conjugating polyethylene glycol to a protein or to a carbohydrate (see Section 5.3, infra.
In preferred nonlimiting embodiments of the invention, following conjugation, the molar ratio of PEG residues per immunoglobulin is at least 50 to 1.
The chemically activated PEG (i.e., PEG rendered capable of covalent linkage by chemical means) used to pegylate the immunoglobulin molecules of the present invention may be any of the many activated forms of PEG known to those skilled in the art, including but not limited to activated mPEG 5000 or activated mPEG 3500. The particular activated PEG used may be of any of the molecular weights known to those skilled in the art. It is preferred that PEG activa¬ tion be achieved via succinimide or triazine.
In a preferred, specific, nonlimiting embodi¬ ment of the invention, chemically activated PEG (i.e., PEG rendered capable of covalent linkage by chemical means) may be covalently linked to an immunoglobulin via lysine residues contained in the immunoglobulin, by the following method:
A 50-fold molar excess of 2,4,6-trichloro-s- triazine activated mPEG 5000 , also known as 2-0- monomethoxypolyphenylene glycol 4,6-dichloro-S-tria- zine, or another size or activated form of PEG, may be added to a solution of the immunoglobulin to be con¬ jugated in 0.1M tetraborate buffer, pH 9.6, stirred vigorously for four hours at room temperature (in one specific nonlimiting embodiment, at least 18°C) , and then concentrated using an ultrafiltration/concen- tration apparatus having a 100,000 molecular weight cut off ("MWCO") . In a specific, nonlimiting embodiment, a
50-fold molar excess of 2,4,6-trichloro-s-triazine activated mPEG 5000 may be added to a solution of 10 mg of the immunoglobulin to be conjugated in 10 ml of 0.1M tetraborate buffer, pH 9.6, stirred vigorously for four hours at room temperature, and then concentrated to 1.5 ml in a CENTREX UF-2 ultraconcentrator of 100,000 MWCO (Schleicher & Schuell) .
In pegylating an immunoglobulin molecule containing an immunogenic heterologous polypeptide corresponding to a T cell or a B cell epitope, it is preferred that the amount of pegylation be effective for increasing the half-life of the immunoglobulin molecule without substantially decreasing the bio¬ logical activity of the immunoglobulin molecule or the immunogenicity of the heterologous peptide. Prefer¬ ably, the amount of pegylation should be effective for increasing the immunogenicity of the heterogenous pep¬ tide without substantially decreasing the biological activity of the immunoglobulin molecule. It is also preferred that the amount of pegylation be effective for conferring to the immunoglobulin molecule an ability to elicit a immune response to the heterologous peptide in a subject, when the immunoglobulin molecule is introduced into the subject without an adjuvant.
In one example, when the pegylation occurs via epsilon amino groups of the lysine residues that are accessible for pegylation, approximately 4 to 10 % of all the accessible epsilon amino groups of lysine residues are pegylated. In the most preferred example, approximately 6 to 8 % of the accessible epsilon amine groups of lysine residues are pegylated.
The degree of mPEG derivatization may be estimated by fluorescamine assay as described in Cunningham-Ruddles et al., 1992, J. Immunol. Methods 152:177. In a specific, nonlimiting embodiment, graded amounts (e.g... 0.25, 0.5, and l microgram) of immuno-
globulin-mPEG conjugate may be dissolved in 25 micro¬ liters of PBS and mixed with an equal volume of fresh fluorescamine in acetone (150g/ml) . Samples may then be incubated for 5 minutes at room temperature and then adjusted to 1 ml with PBS. The absorbance may then be measured at 475 nm emission versus 390 nm excitation and the percent of pegylated residues may be estimated by the formula:
1 - {(OD475 Ig-mPEG / OD475 native Ig) x 100}
Preparations of PEG-immunoglobulin conjugates may then be purified to substantially remove unreacted PEG as well as any undesirable products of the con¬ jugation process, such as residual adducts.
For example, and not by way of limitation, where PEG is conjugated to immunoglobulin via lysine residues using 2,4,6-trichloro-s-triazine activated mPEG 5000, as set forth above, the following two-step method of purification may be used. First, residual unreacted mPEG may be removed by, for example, size exclusion chromatography, ultrafiltration, or dialysis followed by either anion exchange chromatography, hydrophobic chromatography, or reverse phase chroma¬ tography., for example, but not by way of limitation, on an AcA44 Ultogel column which has been equilibrated with 0.1 M ammonium hydrogencarbonate, pH 8.5 and flow- rate of 0.4 ml/min. It is desirable to remove unreacted mPEG prior to any attempt to remove residual adducts by chromatography, as the presence of unreacted PEG could interfere with the removal of such adducts. As a specific, nonlimiting example, unreacted mPEG may be removed as follows. The products of conjugation reac¬ tion may be applied to an AcA44 Ultrogel filtration column (80 x 1.6 cm) which has been equilibrated with 0.1M NH4HC03, pH 8.5 and a flow rate of 0.4 ml per minute. Fractions of eluate may then be collected at 4 minute intervals, dried by speed vacuum centrifugation
and resuspended in 0.5 ml of 5 mM sodium acetate, pH 5.0. Each fraction may then be analyzed for protein content by, for example, Biuret micro assay, and for the presence of free hydrolyzed mPEG by Nessler's reagent, as described in Wilkinson et al., 1987, Immunol. Lett. .15:17-22. Fractions of the conjugates which are found to be free of hydrolyzed mPEG may then be subjected to a second chromatography step to remove residual adducts. In this second step, fractions of conjugates found to be free of hydrolyzed mPEG may then be applied to a Q300 anion exchange HPLC column (or a similar anion exchange column) which has been equil¬ ibrated with 5 mM sodium acetate, pH 5 using a 45 minute linear gradient from 5 to 500 mM sodium acetate, pH 5, and a flow rate of 0.5 ml/min. Fractions from the Q300 column may then be dialyzed in Spectrapor bags with 75,000 MWCO against PBS and concentrated in CENTREX UF-2 tubes. Other methods, such as those set forth for removing unreacted PEG, could also be used to remove residual adducts. Fractions containing useful PEG-IG conjugates may be identified, for example, by fluorescamine assay, mass spectroscopy, proton NMR, or SDS-PAGE.
It may further be desirable to confirm the homogeneity of the purified immunoglobulin-PEG con¬ jugates by SDS-PAGE under non-reducing conditions (Lae mli, 1970, Nature 227:680-685).
5.2. NON-IMMUNOGLOBULIN MOLECULES
The present invention further provides for pegylation of non-immunoglobulin molecules, where polyethylene glycol is conjugated to a non-immunoglo¬ bulin molecule via carbohydrate residues, using enzym¬ atic methods as set forth in section 5.3., infra.
Examples of non-immunoglobulin molecules which may be pegylated in this manner include, but are not limited to, proteins which are naturally or arti-
ficially glycosylated. Proteins which are, or may be rendered, glycosylated include bacterial, viral, pro- tozoal, yeast, funal or insect proteins, proteins expressed in cells of lower or higher vertebrates, receptor proteins, signal transductions proteins, cyto¬ kines, enzymes, membrane proteins, etc.
5.3. ENZYMATIC METHODS OF PEGYLATION The present invention also provides for an enzymatic method which may be used to couple PEG to an immunoglobulin or non-immunoglobulin protein. Accord¬ ing to this method, PEG may be linked to an oxidized carbohydrate residue (such method referred to as "gly- copegylation") on a protein molecule thereby minimizing the distortion of peptide portions of the protein that may be the result of pegylating amino acid primary amines. Such an oxidized carbohydrate residue may be formed by reacting a glycosylated (e.g. natively glycosylated) immunoglobulin molecule with a sugar oxidase enzyme. In a particular, nonlimiting embodiment of the invention, immunoglobulin-Gal-PEG conjugates (Ig-Gal-PEG) may be synthesized by oxidizing a galactose (Gal) residue of an asialo- or desialylated Ig with galactose oxidase (GAO) , and then forming a Schiff base between the C6-aldehyde group of the Gal residue and an amino terminal group of Gly-PEG, with concurrent reductive alkylation of the imidic bond by reduction with pyridine borane (PB) . This method is diagrammed in Figure 11. Section 8, infra, provides a specific example of this method, in particular, the synthesis of human and mouse Ig conjugates with an amino acid derivative of PEG 3,400 (Gly-PEG). 5.4. UTILITIES OF THE INVENTION In a first set of embodiments, the present invention provides for a method of enhancing an immune response toward a heterologous peptide in a subject, comprising administering, to the subject, an effective
amount of purified immunoglobulin molecule containing the heterologous peptide, wherein at least 5 percent of the lysine residues of the immunoglobulin molecule are covalently linked to polyethylene glycol.
The pegylated immunoglobulins of the present invention may be useful in the diagnosis and treatment of a wide variety of malignancies and viral infections.
Accordingly, the present invention provides for a method of treating a viral (or bacterial, proto¬ zoan, mycoplasmal, or fungal) infection comprising administering, to a subject in need of such treatment, an effective amount of a composition comprising pegy¬ lated immunoglobulin, as described in the preceding sections, containing a heterologous peptide which com¬ prises an epitope of a viral, bacterial, protozoan, mycoplasmal, or fungal antigen. The term "treating" as used herein refers to an amelioration in the clinical condition of the subject, and does not necessarily indicate that a complete cure has been achieved. An amelioration in clinical condition refers to a pro¬ longed survival, a decreased duration of illness, or a subjective improvement in the quality of life of the subject.
The present invention provides for a method of enhancing an immune response directed toward a viral, protozoan, mycoplasmal, bacterial or fungal pathogen, in a subject in need of such treatment, com¬ prising administering, to a subject in need of such treatment, an effective amount of a composition comp¬ rising pegylated immunoglobulin, as described in the preceding sections, containing a heterologous peptide which comprises an epitope of a viral, protozoan, myco¬ plasmal, bacterial, or fungal antigen. The phrase "enhancing an immune response" refers to an increase in cellular and/or humoral immunity. In preferred embodi¬ ments, the amount of cellular and/or humoral immunity
is increased in the subject by at least 25 percent. Such an enhanced immune response may be desirable during the course of infection, or before infection may have occurred (for example, in the context of a vac¬ cine) .
The present invention also provides for a method of treating a malignancy or other neoplasm com¬ prising administering, to a subject in need of such treatment, an effective amount of a composition com¬ prising pegylated immunoglobulin, as described in the preceding sections, containing a heterologous peptide which comprises an epitope of an antigen associated with a malignancy or neoplasm. In addition to the definition of "treating" set forth above, tumor regres¬ sion, such as a decrease in tumor mass or in the number of metastases, of preferably at least 25 percent would be considered "treating".
Further, the present invention provides for a method of enhancing an immune response directed toward a malignancy or other neoplasm, in a subject in need of such treatment, comprising administering, to a subject in need of such treatment, an effective amount of a composition comprising pegylated immunoglobulin, as described in the preceding sections, containing a heterologous peptide which comprises an epitope of an antigen associated with a malignancy or neoplasm.
As with all pharmaceutical compositions, the effective amounts of the pegylated immunoglobulins of the invention may be determined empirically. Factors to be considered include the condition to be treated, whether or not the antibody will be complexed with or covalently attached to a toxin, route of administration for the composition, i.e. intravenous, intramuscular, subcutaneous, etc. , and the number of doses to be administered. Such factors are known in the art and it
is well within the skill of physicians to make such determinations without undue experimentation.
The pegylated immunoglobulins of the inven¬ tion offer a number of in vitro utilities, and the invention provides for methods based on such utilities. Such utilities include, for example, radioimmunoassays and ELISA assays, and fluorescence activated cell sorting.
In a second set of embodiments, the half-life of non-immunoglobulin molecules may be extended by enzymatic pegylation of carbohydrate residues on the non-immunoglobulin molecules. For example, but not by way of limitation, the half-life of a viral protein may be extended by such pegylation, such that a vaccine comprising the viral protein may become more antigenic. As a second example, an enzyme may be rendered more stable by such pegylation, so that the enzyme may be used more effectively in either enzyme supplementation therapy in vivo, or in diagnostic or therapeutic appli¬ cations.
The following examples are meant to illus¬ trate but not limit this invention.
6. EXAMPLE: DERIVATIZATION OF CHIMERIC IMMUNOGLOBULINS WITH PEG
6.1. MATERIALS AND METHODS
Mice. Six week old BALB/c mice were pur¬ chased from Jackson Laboratory (Bar Harbor, ME) .
Antigens. The synthetic peptide HA110-120 (SFERFEIFPKE; SEQ ID NO:7) corresponds to amino acid residues 110-120 of the hemagglutinin (HA) of PR8 influenza A virus (Zaghouani et al., 1993, Science 259:224), NP 147-161 (TYQRTRALVRTGMDP; SEQ ID N0:16) corresponds to residues 147-161 of the nucleoprotein (NP) of PR8 influenza A virus (Zaghouani et al., 1992,
J.Immunol., 148: 3604) and V3C peptide (RKSIHIGPGRAFYTTGEII; SEQ ID NO:l) corresponds to a consensus sequence predicted from the comparison of the V3 cysteine bridged loop sequences of gpl20 envelope proteins of 245 HIV-1 isolates. Peptides were syn¬ thesized and RP-HPLC purified at IAF Biochem (Laval, Quebec, Canada) . KLH and BSA conjugates of the syn¬ thetic peptides were prepared using standard tech¬ niques.
Chi eric Immunoglobulins. Ig-HA and Ig-V3C are genetically engineered chimeric immunoglobulins. Ig-HA is a BALB/c IgG2b expressing, in the CDR3 loop, a T cell epitope (consisting of the HA110-120 peptide) from the HA of PR8 influenza A virus. Ig-NP is also a BALB/c IgG2b expressing, in the CDR3 loop, the NP147- 161 CTL-epitope consisting of the NP147-161 peptide. Ig-V3C is a chimeric immunoglobulin comprising mouse variable and human γl/k constant regions, and con¬ taining, within the heavy chain CDR3 loop, a B cell epitope from the V3 cysteine bridged loop of the envelope protein of HIV-1. Ig-W is a chimeric immuno¬ globulin comprising wild type mouse VH and VL variable regions and human γl/k constant regions, which was used as a control for Ig-V3C. Ig-HA and Ig-NP were affinity purified from cell culture supernatant on a rat anti- mouse k chain-sepharose column. Ig-V3C and Ig-W were affinity purified on a mouse anti-human k chain anti¬ body (HP605)-sepharose column.
Virus. PR8 influenza A virus was prepared from allantoic fluid of embryonated eggs on a sucrose gradient. An UV inactivated PR8 virus was used in these experiments.
Derivatization of chimeric Ig with mPEG. Ig- HA, Ig-NP, and Ig-V3C (see above) were derivatized with 2,4,6-trichloro-s-triazine activated mPEG 5,000 (Sigma) and purified to homogeneity. Briefly, a 50 times molar
excess of mPEG was added to 10 mg of chimeric immuno¬ globulin in 10 ml of 0.1M tetraborate buffer, pH 9.6. The mixture was stirred vigorously for four hours at room temperature and the preparations were concentrated to 1.5 ml in CENTREX UF-2 ultraconcentrators of 100,000 MWCO (Schleicher & Schuell) . The residual unreacted mPEG was removed by size exclusion chromatography on an AcA44 Ultrogel column and homogeneous populations of Ig-mPEG with 6-8% derivatized lysines were isolated by anion exchange HPLC on Q300 column (for details of pro¬ cedure, see Example Section 7, below). The degree of mPEG derivatization was estimated by fluorescamine assay as described in Cunningham-Rundles et al., 1992, J.Immunol. Methods 152:177. Briefly, graded amounts (0.25, 0.5 and lμg) of Ig-HA-mPEG, Ig-V3C-mPEG conju¬ gates and native Ig-HA or Ig-V3C, were dissolved in 25 μl of PBS and mixed with an equal volume of fresh fluorescamine in acetone (150 g/ml) . Samples were incubated for 5 min at room temperature and then adjusted to 1 ml with PBS. The absorbance was then measured at 475 nm emission versus 390 nm excitation and the percent of pegylated lysines was estimated according to the following formula: l-[(OD475 Ig-mPEG / OD475 native Ig)xl00]. The homogeneity of the conju¬ gates was confirmed by SDS-PAGE and agarose electro¬ phoresis.
Blood circulation. Ig-HA and Ig-HA-mPEG preparations (lOOμg in lOOμl of PBS) were radiolabeled with 125I using the chloramine method and the free iodine was then removed by gel filtration on PD10 col¬ umns (Pharmacia) . Groups of three BALB/c mice were injected intravenously with 200μl of PBS containing 20 x 106 cpm (4μg) of 125I-labeled native Ig-HA or Ig-HA- mPEG. Fifteen minutes later (time required for uniform distribution of labeled Ig) the mice were bled and the radioactivity in 20μl of serum was counted. Total
radioactivity per mouse was estimated on the basis that 7.3% of body weight is blood and 55% of the blood vol¬ ume is serum (Klibanov et al., 1991, Biochim. Biophys.Acta 1062: 142). The radioactivity estimated at 15 min was considered as the total radioactivity injected. To investigate the clearance of Ig-HA and Ig-HA-mPEG, mice were bled 3, 6, 24, 48, 72, and 168 hours after injection. Blood clearance rates were expressed for each group as percentage of residual radioactivity at various intervals of time.
Organ distribution. To study the tissue distribution of the native Ig-HA and Ig-HA-mPEG conjugates, two groups of seven mice each (15-17g weight) were injected intravenously with 200μl PBS containing 20 x 106 cpm of 125I-labeled native Ig-HA or Ig-HA-mPEG. Mice were bled after 15 min and the blood radioactivity was estimated as above. Fragments of liver, spleen, lung and kidney were then resected by 3, 6, 24, 48, 72, and 168 hours after inoculation and the radioactivity was measured in a γ counter. Tissue distribution was expressed as index of distribution (%ID) of 125I-Ig-HA or 1251-Ig-HA-mPEG. ID represents the percentage of radioactivity per gram of wet organ versus the radioactivity measured in blood at 15 min after injection (Kitamura et al., 1990, Biochem. Biophys. Res. Commun.: 1387).
Western blot analysis. To investigate in vivo proteolysis of the native and pegylated Ig-HA, blood samples from mice injected with 125I-Ig-HA or 125I-Ig-HA-mPEG as for the clearance studies, were analyzed by SDS-PAGE under non- reducing conditions. Briefly, serum samples (5μl) collected at various intervals of time were electrophoresed on 8 to 17% polyacrylamide gradient gels (ExcelGels, Pharmacia) for 2 hours, at 150 volts and 40°C using a Multiphore II system (Pharmacia) . Separated proteins were electro-
transferred from the gel onto PVDF membranes (0.22μ, Millipore, Waters Co.) for 30 minutes at 450 mAmps. Membranes were dried and exposed to Kodak X-OMAT films overnight at -70°C.
In vitro T cell proliferation assay. 2PK3 B lymphoma cells (H-2d) were used as antigen presenting cells ("APCs"). Irradiated (2,200 rads) APCs (104) were incubated for 48 hours in round bottom 96-well plates with graded amounts of Ig-HA, Ig-HAmPEG or Ig- NP-mPEG, and 2 x 104 of HA110-120 specific T hybridoma cells LDl-24 (Haberman et al., J. Immunol. 145:3087). Supematants were then harvested and IL-3 production, as a measure of T cell proliferation, was determined using 1.5 X 104 of IL-3 dependent DA- I cells and the calorimetric MTT assay (Zaghouani et al., Science 259:224, Mosmann, 1983, J. Immunol. Methods 65: 55).
In vivo T cell proliferation assay. The pro¬ liferative response of lymph node cells from BABL/c mice immunized with Ig-HA or Ig-HA-mPEG were assessed for [3H]-thymidine incorporation. Four groups of seven mice each were immunized subcutaneously at the base of the tail and in the foot pads with lOOμg of Ig-HA or Ig-HA-mPEG emulsified in either 200μl of PBS or 200μl of PBS/CFA (1:1 v/v). Ten days later, the draining lymph nodes were collected and the cells were cultured in flat bottom 96-well microtiter plates (2 x 105 cells per well) with 0.5, 1, 5, and lOμg/ml of HA110-120, NP147-161, Ig-HA, Ig-NP, UV-inactivated PR8 virus, ConA (lμg/ml) or no antigen. Cultures were set up in quad¬ ruplets from pooled lymph node cells, incubated under standard conditions for 5 days (or 3 days in the case of ConA) , and pulsed for the last 18 hours with 1 μCi of [3H]-thymidine per well. The cells were then har¬ vested and the radioactivity was measured in a β scintillation counter. The mean of cpm obtained in the
absence of antigen was subtracted from the mean of cpm obtained in the presence of antigens.
Radioimmunoassay. Detection of the anti-V3C peptide antibodies in mice sera was carried out by radioimmunoassay as follows: microtiter plates were coated with 50μl of PBS containing 5μg/ml of V3C pep¬ tide coupled to BSA (V3C-BSA) , BSA, or NP147-161-BSA for 18 hours at 40°C. The plates were extensively washed with PBS and then blocked with 3% BSA in PBS at room temperature. After 4 hours the plates were washed with PBS and serial serum dilutions (50μl) in 1% BSA- PBS were added. The plates were incubated for 2 hours at 37°C. After washing with PBS-0.05% Tween 20, bound antibodies were revealed by incubating the plates for 2 hours at room temperature with 5 x 104 cpm of 1 5I-rat anti-mouse k chain mAb. Plates were then washed and bound radioactivity was measured in a γ counter. The amount of anti-V3C antibodies in mice sera was estima¬ ted by extrapolation on a standard curve constructed with affinity purified mouse polyclonal anti-V3C anti¬ bodies. These polyclonal anti-V3C antibodies were obtained from BALB/c mice immunized with V3C-KLH con¬ jugate (100 μg) in CFA and then boosted weekly, three times with V3C-KLH conjugate (50μg) in Incomplete Freund adjuvant (IFA) . The antibodies were affinity purified on a V3C-BSA-sepharose column.
Detection of anti-human isotypic antibodies in mice sera was carried out by radioimmunoassay as follows: microtiter plates were coated with 50μl of PBS containing 2μg/ml of Ig-W for 18 hours at 40°C. The plates were then treated as above. The amount of mouse anti-human Ig antibodies was estimated by extrapolation on a standard curve constructed with a stoichiometric mixture of mouse anti-human γl mAb (Zymed Laboratory) and HP6053 mouse anti-human kappa mAb (ATCC) .
6.2 . RESULTS
Preparation of homogeneous populations of pegylated chimeric immunoglobulins.
Ig-HA and Ig-V3C were mildly pegylated and homogeneous conjugates with 6-8% mPEG substitution of the lysine residues were purified as described in Sec¬ tion 7, below. The conjugate preparations were rendered free of residual adducts such as free hydro¬ lyzed mPEG and highly conjugated or unconjugated immunoglobulin by size exclusion chromatography per¬ formed on AcA44 Ultrogel column followed by anion- exchange HPLC on Q300 column. Homogeneous populations of Ig-HA-mPEG and Ig-V3C-mPEG conjugates with 6-8% mPEG substituted lysine residues as determined by fluores¬ camine assay, were used for further investigations.
Blood clearance and tissue distribution of native and pegylated chimeric immunoglobulins.
Clearance rates . The clearance rates of Ig¬ HA-mPEG from blood circulation were analyzed in paral¬ lel to those of native Ig-HA. 125I-labeled Ig-HA-mPEG and Ig-HA were injected intravenously into BALB/c mice and the radioactivity was measured in blood samples collected at various intervals of time. As depicted in Figure 1, native Ig-HA was cleared at 48 hours after injection while Ig-HA-mPEG persisted in peripheral blood up to 7 days. Ig-HA-mPEG showed a two phase clearance characterized by an initial rapid decline followed by a much slower decline.
Resistance to £n vivo proteolysiε . Serum samples from mice injected with 125I-labeled native Ig- HA or Ig-HA-mPEG were collected at various intervals of time and analyzed by Western blot analysis. Both native and pegylated Ig-HA showed significant degrada¬ tion between 6 and 24 hours after injection. By 48
hours, the majority of the proteolytic products were cleared from the blood, and by 72 hours intact immuno¬ globulin molecules were detected only in samples from mice injected with Ig-HA-mPEG (Figure 2) .
Tissue distribution . We carried out kinetic studies to estimate the amount of radioactivity in various tissues at various intervals of time after injection of the radiolabeled conjugates. The tissue distribution of 125I-Ig-HA and 1251-Ig-HA-mPEG was studied in liver, spleen, lung and kidney resected at 0.25, 3, 6, 24, 48, 72 and 168 hours after injection. As illustrated in Figure 3, both Ig-HA and Ig-HA-mPEG were taken up by the various organs to the same extent but the amounts of Ig-HA-mPEG retained in the organs were higher than those of native Ig-HA. It should be noted that in lungs, while Ig-HA-mPEG was still present by 168 hours, the native Ig-HA was cleared by 72 hours. Overall, these results indicate that pegylated Ig-HA molecules persist longer than the native Ig-HA in the blood, and higher amounts of the pegylated Ig-HA were retained in organs with lymphoid tissues.
The cellular immune response to HA110-120 peptide expressed by pegylated Ig-HA chimera.
In vitro activation of HA110-120 specific T cell hybridoma . To assess the effect of mPEG deriva- tization on the immunogenicity of Ig-HA, we studied in vitro T cell activation by native Ig-HA and Ig-HA-mPEG. This was carried out using HA110-120 specific T hybri¬ doma cells (LDl-24 cells) and measurement of IL-3 release by these cells subsequent to activation by the various antigens. Figure 4 shows that Ig-HA-mPEG activated the specific T cells to the same extent as native Ig-HA. This indicates that mPEG derivatization of the chimeric Ig did not affect the delivery and sub¬ sequent presentation of the HA100-120 peptide to the T
cells. No activation was observed with pegylated Ig- NP, a molecule carrying a CTL epitope from NP of PR8 influenza A virus instead of the HA110-120 helper epi¬ tope.
In vivo priming of HA11O-120 specific T cells . Immunization of BALB/c mice with Ig-HA in CFA primed animals results in a specific proliferative response (Zaghouani, et al., 1993, Science 259:224). In this study, we compared the immunogenicity of native and pegylated Ig-HA administered in either saline or CFA (Figure 5) . Lymph node cells from BALB/c mice were harvested ten days after immunization and stimulated in vitro for 5 days with various antigens. Immunization with native Ig-HA in CFA primed T cells resulted in an in vitro proliferative response upon incubation with Ig-HA, UV-inactivated PR8 virus and HA110-120 peptide but not Ig-NP or NP 147-161 peptide (Figure 5b) . Similar responses were obtained when the mice were primed with Ig-HA-mPEG in CFA (Figure 5d) .
More strikingly, a strong and specific pro¬ liferative response was obtained when the mice were primed with Ig-HA-mPEG in saline (Figure 5c) . No response was detected when the mice were immunized with native Ig-HA in saline (Figure 5a) . This strongly sug¬ gests that the requirement for adjuvant was obviated when Ig-HA was derivatized with mPEG 5,000.
Effect Of Ig-V3C derivatization with mPEG on the antibody response to
V3C peptide and to Ig-xenogeneic determinants
The kinetics of the antibody response elici¬ ted by native and pegylated Ig-V3C was studied in BALB/c mice following different immunization schedules (see the legend for Figure 6) . As mentioned above, Ig- V3C is a chimeric molecule made up of murine VH gene expressing the consensus V3C peptide, murine Vk gene and
human γl and constant region genes. Therefore, we measured by RIA the antibody response against the V3C epitope as well as against isotypic determinants of human constant regions.
The study showed a sharp increase of the antibodies to V3C peptide after immunization with Ig- V3C-mPEG in CFA followed by a boost in IFA (Figure 6a) . More importantly, immunization of animals with Ig-V3C or Ig-V3C-mPEG in saline induced a V3C specific antibody response (Figures 6b, 6c, and 6d) . This response was slightly higher in animals immunized with Ig-V3C-mPEG. The antibody response was stronger when the animals were immunized 3 times in saline (Figure 6b versus Figures 6c and 6d) .
The animals immunized with native chimeric Ig in CFA showed high antibody response to isotypic deter¬ minants of human constant regions (Figure 6e) . How¬ ever, while immunization in saline with native Ig-V3C also induced a strong anti-human antibody response, immunization with Ig-V3C-mPEG in saline elicited no significant response (Figures 6f, 6g and 6h) .
7. EXAMPLE: PURIFICATION OF PEGYLATED IMMUNOGLOBULIN During pegylation of a protein, various degrees of derivatization may occur as a consequence of the micro heterogeneity of the protein, the distri¬ bution of both the number and the position of attach¬ ment of PEG units, the inherent polydispersity of PEG polymers, and microenvironmental conditions of the reaction. In addition, deoxy PEG that can crosslink proteins may be present in commercial preparations as a result of hydrolysis of the ethylene oxide monomers during the polymerization process (Selisko et al., 1993, J. Chromatogr. 641: 71-79; Harris et al., 1985, in "Partitioning in Aqueous Two-Phase Systems", D.E. Brooks and D. Fisher (Editors), Academic Press,
Orlando, Fl., p.593). Thus, protein-mPEG preparations may contain species of highly pegylated and/or cross¬ linked proteins in addition to the residual adducts. Purification of homogeneous populations of conjugates is therefore required prior to their use in biological systems. Purification of protein-PEG conjugates has generally consisted of a single step chromatographic removal of free PEG polymers (Kitamura, et al., 1991 Cancer Res., 51: 4310-43115; Cunningham-R.A.et al., 1992, J. Immunol. Methods, 152: 177-190; Snider et al., 1992, J. Chromatogr. 599: 141-155; Jackson, et al., 1987, Anal-Biochem. 165:114-127). Herein, we des¬ cribe a two step procedure able to remove completely the residual adducts and to isolate homogeneous popu¬ lations of mPEG derivatized immunoglobulins.
7.1. MATERIALS AND METHODS Materials. AIgs (Ig-HA and Ig-V3C) were generated in our laboratory as described above. PhastSystem electrophoresis apparatus, PhastGels 4-15% gradient of polyacrylamide and cyanogen bromide activa¬ ted Sepharose CL-4B were purchased from Pharmacia, LKB. AcA44 Ultrogel and dialysis bags of 75,000 MWCO were from Spectrum, Co. Ultra concentrators of 100,000 MWCO (CENTREX UF-2, 2ml volume) were from Schleicher & Schuell. Rat hybridoma cells secreting monoclonal anti-murine k chain antibodies and HP6053 mouse hybri¬ doma producing anti-human k chain antibodies were from ATCC. The Q300 HPLC column (250 x 4.6 mm, 300 micron particle size) was from Rainin. Nessler reagent and 2,4,6-trichloro-s-triazine activated monomethoxypoly- ethylene glycol MW 5,000 (mPEG 5,000) were from Sigma. The agarose gels (Titan Gel High-Resolution Protein kit) were from Helena Laboratories.
Purification of AIgs. IgHA and Ig-V3C were affinity purified on a rat anti-murine k chain and
mouse anti-human k chain antibody-Sepharose columns, respectively. Affinity purified AIgs were equilibrated in 0.IM sodium tetraborate, pH 9.6 and concentrated to 1 mg/ml by ultracentrifugation using tubes of 100,000 MWCO.
Derivatization of AIgs with mPEG. 10 mg of each Alg were derivatized with 2,4,6-trichloro-s- triazine activated mPEG 5,000 as described in Jackson, et al., 1987, Anal-Biochem. 165:114-127. Briefly, a 50 times molar excess of mPEG was added to 10 mg AIgs in 10 ml of 0.1M tetraborate buffer, pH 9.6. The mixture was stirred vigorously for four hours at room tempera¬ ture. The conjugate preparations were concentrated to 1.5 ml in tubes of 100,000 MWCO and further purified.
Chromatographic purification of Alg-mPEG conjugates. Alg-mPEG preparations were applied to a AcA44 Ultrogel filtration column (80 x 1.6cm) equili¬ brated with 0.1M NH4HC03, pH 8.5 and flow rate of 0.4 ml/min. Fractions were collected at 4 min interval, dried by speed vacuum centrifugation and resuspended in 0.5 ml of 5mM sodium-acetate, pH 5. Each fraction was then analyzed for protein content by Biuret micro assay, and for the presence of free hydrolyzed mPEG by Nessler's reagent as described in Wilkinson et al., 1987, Immunol.Lett. 15: 17-22. Fractions of the conjugates free of hydrolyzed mPEG were then rechro- matographed on a Q300 anion-exchange HPLC column equilibrated with 5 mM sodium acetate, pH 5 using a 45 minutes linear gradient from 5 to 500 mM sodium ace¬ tate, pH 5, and flow rate of 0.5 ml/min. Fractions from the Q300 column were dialyzed in Spectrapor bags with 75,000 MWCO against PBS and concentrated in CENTREX UF-2 tubes.
Electrophoretic analyses of Alg-mPEG conju¬ gates. Homogeneity of Alg-mPEG conjugates were anal¬ yzed by SDS-PAGE and residual mPEG was detected by
electrophoresis on agarose gels. The SDS-PAGE was performed under non-reducing conditions as described by Laemmli (Laemmli, 1970, Nature (London), 227: 680-685). Briefly, Samples (5 μg) were resuspended in 5 μl of sample buffer (0.1% SDS, 0.1M Tris-HCl 6M urea, pH 8.5) and incubated at 37°C for 2 hours. Samples were run on 4-15% gradient PhastGel (Pharmacia) at 250 Volts and 5 Watts for 45 minutes at 15°C. The gel was then fixed and silver stained. Electrophoresis on agarose Titan gels was carried out according to the manufacture's instructions. Samples (10 μg in 5 μl barbital buffer) were run at 250 Volts for 30 minutes on duplicate gels. One gel was stained with a mixture of 0.1% Coomassie Blue R-250 and 1% Ponceau S, and the second gel was immersed in 20% trichloroacetic acid (TCA) in water for 30 seconds and immediately photo-scanned.
Fluorescamine assay. Graded amounts (1, 0.5 and 025 μg) of Alg-mPEG or AIgs in 25 μl of PBS were mixed with equal volume of fresh fluorescamine in ace¬ tone (150 g/ml) and incubated for 5 min at room temperature. Samples were then brought to 1 ml with PBS and absorbency was measured at 475 nm emission versus 390 nm excitation. The percent of pegylated primary amines was estimated according to the following formula l-(OD475AIgs-mPEG/OD475AIgs)xlOO (Neville, et al., 1991, presented at the American Association of Pharmaceutical Scientists', Sixth Annual Meeting, Washington, DC, Nov. 17-21, 1991) . The improved reso¬ lution obtained with ammonium bicarbonate may be related to better neutralization of the active charges on the gel matrix and therefore lower interactions between free mPEG polymer and the matrix.
7.2. RESULTS Removal of other residual adducts from the Alg-mPEG conjugates. Because no one step procedure for
the separation of protein-mPEG conjugates from residual adducts has been described, we chose a method that includes a first step removal of hydrolyzed mPEG and a subsequent step that removes other residual adducts such as underivatized or highly derivatized AIgs. Since the size exclusion limit of the AcA44 Ultrogel column is 140 kD, hydrolyzed mPEG can be removed but the other residual adducts can not. The removal of excess PEG is required because it could interfere with the isolation of the conjugates from the other residual adducts in the subsequent anion exchange chromatography step. Preliminary experiments performed on anion- exchange HPLC columns as a single step of purification, showed poor resolution and low yields even if minimal amounts of sample were applied on the column. In fact, the conjugates showed a broad elution profile as a result of the presence of excess of free polymers which interfere strongly with the binding of conjugates to the anion-exchange matrix. Poor resolution of pegy¬ lated proteins was also described when conjugates were separated by charge-reversal capillary zone electro¬ phoresis without previous removal of free PEG (Snider et al., 1992, J. Chro atogr. 599: 141-155; McGoff, et al., 1988, Chem.Pharm.Bull. 36: 3079). It may be important to remove free polymer from the conjugate preparation in order to obtain good resolution in dif¬ ferent separating media.
To select a homogeneous population of con¬ jugates with 6-8% degree of pegylation, we rechroma- tographed the conjugates on anion-exchange HPLC column with optimized conditions as described in the experi¬ mental section. Figure 7 shows the elution profiles of Ig-HA-mPEG (Figure 7A) and free IG-HA (Figure 7b) . In the case of Ig-HA-mPEG, 3 major peaks were eluted from the column and labeled 1, 2, and 3 (Figure 7a). Peak 3 represents free Ig-HA since it elutes at the same salt
concentration as the unconjugated control Ig-HA. The material of peak 1 may represent highly pegylated AIgs that could not bind to the matrix. Peak 2 contained mildly pegylated Ig-HA as revealed by SDS-PAGE analysis (see below) .
Analysis of the homogeneity of Alg-mPEG conjugates. The purity of Algs-mPEG preparations was further analyzed for the presence of traces of free mPEG and residual adducts performed on agarose and polyacrylamide gel electrophoresis, respectively. Although purification of Algs-mPEG conjugates followed one step purification by size exclusion chromatography, small amounts of free mPEG that could not be detected by Nessler's test may be present in the conjugate preparations. To trace small amounts of free PEG that could interfere with the immunogenicity of the Algs- mPEG we developed an original, sensitive electro- phoretic technique able to detect μM of free mPEG. Based on the observation that mPEG migrate on agarose to the cathode and can be visualized by TCA precipi¬ tation but not by protein dyes, we attempted to trace free mPEG in our preparation by electrophoresis on a Titan gel HRT kit followed by TCA precipitation. As can be seen in Figure 8, left panel, an Ig-HA-mPEG preparation obtained from the second chromatographic purification (lane 1) like unpegylated Ig-HA pre¬ paration (lane 2) , did not show detectable amounts of free hydrolyzed mPEG while the preparation collected from the first chromatographic purification contained residual free PEG (lane 4) . The amount of free resi¬ dual mPEG, if any, in the final Ig-HA-mPEG preparation (lane 1) should be lower than 4 x 10~4 M. Calibration experiments indicated that as little as 4 x 10" M of mPEG 5,000 can be detected using this technique (lane 3).
When a duplicate gel was stained with Coomas- sie/Ponceau (Fig. 8, right panel), only Ig-HA and Ig¬ HA-mPEG conjugates were revealed (lanes 1, 2, respect¬ ively) but not free hydrolyzed mPEG (lane 3) . Inter¬ estingly, pegylated Ig-HA showed better staining with Ponceau S than unpegylated Ig-HA. The differential staining may be attributed to different ability of the two dyes to access their specific sites on the native protein versus the pegylated one. Using this assay, we also were able to trace free mPEG polymers in pre¬ parations of chicken egg ovalbumin-mPEG, BSA-mPEG and bovine gamma globulin-mPEG conjugates.
Although small amounts of PEG polymers can be detected by sensitive techniques such as Childs' assay (Childs, 1975, Microchem. J. 20: 190-192) or Veronese's test (Schiavon, et al., 1990, M. Farmaco., 45(6): 791- 795) , our electrophoretic technique is able to distinguish free PEG from PEG attached to proteins.
Furthermore we performed SDS-PAGE analysis to investigate the homogeneity of Algs-mPEG preparations. This was carried out on 4-15% gradient gels (PhastGels, Pharmacia) under non-reducing conditions. The results illustrated in Figure 9 show that the final Ig-HA-mPEG and Ig-V3C-mPEG preparation (peak 2 in Figure 7) were purified to homogeneity (lanes 2 and 5 respectively) . These preparations do not contain detectable amounts of unpegylated AIgs because no comigration with free Ig-HA (lane 1) or Ig-V3C (lane 4) was observed. They do not contain highly pegylated AIgs either because no mater¬ ial comigrated with samples representing heavily pegy¬ lated AIgs (from peak 1 in Figure 7) . In summary, we were able to select a homogeneous population of Alg- mPEG with 6-8% degree of pegylated as indicated by these electrophoretic analyses.
The pegylated Ig-HA, showed a long half life and induced strong T cell activation in mice in vivo .
8. EXAMPLE: ENZYMATIC DERIVATIZATION OF IMMUNOGLOBULINS WITH PEG
As set forth in the preceding sections, immunoglobulins have been found to exhibit a remarkable increase in half-life when 6 - 8% of the primary amines are chemically conjugated to mPEG 5,000. However, whereas such mild pegylation may preserve the immunogenicity of hidden determinants on immuno¬ globulins, higher degrees of pegylation may produce undesirable tolerogenic and/or suppressogenic effects for foreign epitopes present on immunoglobulins used for immunization purposes. Tolerization of an immuno¬ genic epitope may occur as a consequence of PEG attach¬ ment to the particular epitope. Similarly, pegylation of a CDR may destroy the functional activity of the CDR. In order to avoid such undesirable effects, PEG has been targeted to carbohydrate moieties found on immunoglobulin molecules in order to increase the half- life of the immunoglobulins while preserving their bio¬ logical activity.
8.1 MATERIALS AND METHODS
Immunoglobulins. Human IgA from colostrum (Sigma) and a rat IgG2b anti-mouse k chain monoclonal antibody were used for glycopegylation in this study. Ig-HA is a BALB/c IgG2b comprising, in the CDR3 loop, a T cell epitope (HA110-120) from the hemagglutinin (HA) of PR8 influenza A virus. igW is a BALB/c IgG2b com¬ prising the unmutated VH region of the anti-arsonate 91A3 mAb. Ig-TB is an Ig-HA chimera in which a HA150- 163 B cell epitope was genetically engineered into the CDR2 loop. To remove traces of IgG in the preparation of IgA, size exclusion chromatography on Superose-6 column was performed as described below. Rat anti- mouse K chain mAb was purified from cell culture super-
natant by affinity chromatography on a mouse anti-rat (MAR 18.5) sepharose column. The genetically engineered chimeras were purified from cell culture supematants by affinity chromatography on rat anti- mouse k chain-sepharose column.
Enzymatic Synthesis of Glycopegylated Igs. Human asialo-IgA colostrum (lmg) in 1 ml of borate buffer 0.1M, pH 9.3 was mixed with galactose oxidase (GAO, Sigma), 25 U/mg of Ig, glycine-PEG 3,500 derivative (Sharewater, U.S.A) at 80 fold molar excess relative to the amount of immunoglobulin present, and 80mM of pyridine borane (PB, Aldrich) . The reaction mixture was incubated overnight at 37°C, with con¬ tinuous stirring. Rat anti-mouse k chain mAb (lmg) was first desialylated with a mixture of neuraminidases (50 mU, 1:1) from Arthrobacter ureafaciens (90.8 U/mg pro¬ tein) , and Clostridium perfringens (4.8 U/mg protein, Calbiochem) by incubating the reaction mixture over¬ night at 37°C with 1ml of phosphate buffer, pH 6 con¬ taining 5 mM of CaCl2. The kinetics of the desialyl- ation reaction may be monitored by determining free NANA released in solution, as described in Warren, 1959, J. Biol. Chem. 234:1971. Free N-acetyl neur- aminic N-acetyl acid (sialic acid, NANA) was then removed by dialysis against 0.1M borate buffer, pH 9.3 and the glycopegylation reaction was continued as for the IgA preparation. A diagram of the reaction is set forth in Figure 11. The glycopegylated Igs (Ig-Gal- PEG) were rendered free of unreacted Gly-PEG by FPLC size exclusion chromatography and then further anal¬ yzed.
Purification of Glycopegylated Igs. Ig-Gal- PEG conjugates were concentrated by speed vacuum cen¬ trifugation and applied to a Superose-6 HR10/30 column (Pharmacia, LKB) equilibrated in PBS at a flow rate of 0.2 ml/min. Fractions were collected every minute and
the tubes containing the conjugates were pooled and tested for protein concentration by Biuret micro-assay and for the presence of free PEG using methods set forth in the preceding sections. The chromatographic profiles were monitored at the maximum absorbance for PEG (254nm) . Ig-Gal-PEG conjugates were concentrated and used for further investigations.
8.2. RESULTS
Electrophoretic Analyses of Ig-Gal-PEG Conjugates. The purity and homogeneity of Ig-Gal-PEG conjugates were analyzed by SDS-PAGE under non-reducing or reducing conditions using methods set forth in the preceding sections. For SDS-PAGE analysis, samples (5 μg) were resuspended in 5 μl of sample buffer (0.1% SDS, 0.1M Tris-HCl 6M urea, pH 8.5) with or without 2- mercaptoethanol (5%) and incubated at 37°C for 2 hours. Samples were run on 4-20% gradient gels (BioRad) at 100 Volts for 60 minutes. A representative resulting gel was then fixed and Coomassie stained (Figure 12) .
To identify charge modifications of the immunoglobulins after glycopegylation, the Ig-Gal-PEG conjugates were analyzed in comparison with native Igs (20μg in lOμl) by isoelectric focusing. Electro¬ phoresis was carried out in 5% polyacrylamide gels (PAG plate, pH 3-10 Pharmacia, LKB) for 90 min at 15°C and 1500 Volts, 50 Watts and 30 mAmps. Gels were stained with Coomassie and photographed (Figure 13) . The pi values were determined on a pi standard curve con¬ structed with a broad pi range standards (Pharmacia, LKB) . Both SDS-PAGE and IEF electrophoregrams were scanned in a Phosphoimage densitometer and the percent of the separated bands was calculated using "Image- Quant" software. Traces of free Gly-PEG, which may remain in the preparation of Ig-Gal-PEG conjugates after purification by size exclusion chromatography, were monitored by electrophoresis on agarose Titan gels
(Helena Labs, TX, Beaumont) using methods set forth in the preceding sections. Briefly, samples (10 μg in 5 μl barbital buffer) were run at 250 Volts for 30 minutes on duplicate gels. One gel was stained with 0.1% Coomassie Blue R-250 and the second gel was immersed in 20% trichloroacetic acid (TCA) in water for 30 seconds for detection of unreacted Gly-PEG (Figure 14).
Estimation of GAO Reactive sites. To estimate the number of galactose sites on carbohydrate moieties of Igs that can potentially participate in the coupling reaction with Gly-PEG, we examined the enzy¬ matic oxidation of Igs using a tilidine-horseradish peroxidase coupled assay system. Briefly, 1ml of a reaction mixture containing either 0.5 mg immuno¬ globulin (e.g., human IgA, rat anti-mouse k chain mAb, mouse IgGl B43.13 mAb), or graded amounts of D- galactose (0.019 to 5 μg) was mixed with 30 U horse¬ radish peroxidase, 0.5 mg tilidine and 2.5 U GAO in 0.IM sodium phosphate at pH 7. The mixture was incu¬ bated for 18 h at 37°C and the absorbance was deter¬ mined at 425 nm. A calibration curve using D-galactose was used to determine the relative "galactose equivalents" on native Igs. Mouse IgGl B43.13 mAb has been used in reaction as a known Ig containing 6.3 nM of galactose residues which corresponds to 4 Gals but showing only 2.1 nM reactive galactose residues (1 residue) . The results of these studies were that the potential galactose sites available for coupling to PEG were four for the rat IgG2b anti-mouse k chain MAB and eight for human IgA from colostrum.
Estimation of GAO Activity in the Presence of Gly-PEG. To determine whether or not Gly-PEG polymer may interfere with the enzymatic oxidation of Gals during the conjugation reaction, we have tested the enzymatic activity of GAO in the presence of graded
amounts of Gly-PEG and using D-Galactose as the sub¬ strate for the enzymatic reaction. A reaction mixture made of GAO (2.5 U) , D-galactose (1 μg) , 30 U horse¬ radish peroxidase, 0.5 mg tilidine and 80mM of pyridine borane (PB) in 0.1M sodium phosphate at pH 7 was incu¬ bated for 18 h at 37°C and the absorbance was deter¬ mined at 425 nm. The same reaction mixture was tested in the presence of graded amounts of Gly-PEG 3,500 corresponding to similar GAO/Gly-PEG molar ratios that may be used in the coupling reaction of Igs with Gly- PEG 3,500 (Figure 16). The results of these studies were that slightly increased GAO activity was observed when PEG was co-incubated in the reaction mixture.
Various publications are cited herein which are hereby incorporated by reference in their entirety.
SEQUENCE LISTING
(1) GENERAL INFORMATION
(i) APPLICANT: MOUNT SINAI SCHOOL OF MEDICINE OF THE CITY UNIVERSITY OF NEW YORK
(ii) TITLE OF THE INVENTION: PEGYLATED MODIFIED PROTEINS
(iii) NUMBER OF SEQUENCES: 16
(iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Brumbaugh, Graves, Donohue & Raymond
(B) STREET: 30 Rockefeller Plaza
(C) CITY: New York
(D) STATE: NY
(E) COUNTRY: USA
(F) ZIP: 10112-0228
(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Diskette
(B) COMPUTER: IBM Compatible
(C) OPERATING SYSTEM: DOS
( D) SOFTWARE: FastSEQ Version 1.5
(vi) CURRENT US APPLICATION DATA:
(A) APPLICATION NUMBER: 08/477,421
(B) FILING DATE: 7-JUNE-1995
(C) CLASSIFICATION:
(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE:
(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Clark, Richard S
(B) REGISTRATION NUMBER: 26,154
(C) REFERENCE/DOCKET NUMBER: 29889-165/29528
(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: 212-408-2558
(B) TELEFAX: 212-765-2519
(C) TELEX:
(2) INFORMATION FOR SEQ ID NO:l:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(iii) ORIGINAL SOURCE:
(A) ORGANISM: Human Immunodeficiency Virus Type 1
(iv) FEATURE:
(A) NAME/KEY:
(B) LOCATION: 301...319
(C) OTHER INFORMATION: Envelope Protein gpl20
(v) SEQUENCE DESCRIPTION: SEQ ID NO:l:
Arg Lys Ser Ile His Ile Gly Pro Gly Arg Ala Phe Tyr Thr Thr Gly
1 5 10 15
Glu Ile Ile
(2) INFORMATION FOR SEQ ID NO:2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(iii) ORIGINAL SOURCE:
(A) ORGANISM: Influenza Virus
(iv) FEATURE:
(A) NAME/KEY:
(B) LOCATION:
(C) OTHER INFORMATION: HAl hemagglutinin protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
Trp Leu Thr Lys Lys Gly Asp Ser Tyr Pro 1 5 10
(2) INFORMATION FOR SEQ ID NO:3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(iii) ORIGINAL SOURCE:
(A) ORGANISM: Influenza Virus
(iv) FEATURE:
(A) NAME/KEY:
(B) LOCATION:
(C) OTHER INFORMATION: H3 protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:
Trp Leu Thr Lys Ser Gly Ser Thr Tyr Pro 1 5 10
(2) INFORMATION FOR SEQ ID NO:4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(iii) ORIGINAL SOURCE:
(A) ORGANISM: Influenza Virus
(iv) FEATURE:
(A) NAME/KEY:
(B) LOCATION:
(C) OTHER INFORMATION: H2 protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:
Trp Leu Thr Lys Glu Gly Ser Asp Tyr Pro 1 5 10
(2) INFORMATION FOR SEQ ID NO:5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide (iii) ORIGINAL SOURCE:
(A) ORGANISM: Measles Virus
(iv) FEATURE:
(A) NAME/KEY:
(B) LOCATION: 404...414
(C) OTHER INFORMATION: F protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:
Ile Asn Gin Asp Pro Asp Lys Ile Leu Thr Tyr 1 5 10
(2) INFORMATION FOR SEQ ID NO:6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(iii) ORIGINAL SOURCE:
(A) ORGANISM: Foot and Mouth Disease Virus
(iv) FEATURE:
(A) NAME/KEY:
(B) LOCATION: 141...160
(C) OTHER INFORMATION: VP1 protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:
Met Asn Ser Ala Pro Asn Leu Arg Gly Asp Leu Gin Lys Val Ala Arg
1 5 10 15
Thr Leu Pro
(2) INFORMATION FOR SEQ ID NO:7:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(iii) ORIGINAL SOURCE:
(A) ORGANISM: Influenza PR8A Virus
(iv) FEATURE:
(A) NAME/KEY:
(B) LOCATION: 110...120
(C) OTHER INFORMATION: Hemagglutinin Protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:
Ser Phe Glu Arg Phe Glu Ile Phe Pro Lys Glu 1 5 10
(2) INFORMATION FOR SEQ ID NO:8:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(iii) ORIGINAL SOURCE: (A) ORGANISM:
(iv) FEATURE:
(A) NAME/KEY:
(B) LOCATION:
(C) OTHER INFORMATION: Tetanus Toxoid Protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:
Asn Ser Val Asp Asp Ala Leu Ile Asn Ser Thr Lys Ile Tyr Ser Tyr
1 5 10 15
Phe Pro Ser Val 20
(2) INFORMATION FOR SEQ ID NO:9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(iii) ORIGINAL SOURCE: (A) ORGANISM:
(iv) FEATURE:
(A) NAME/KEY:
(B) LOCATION:
(C) OTHER INFORMATION: Tetanus Toxoid (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:
Pro Glu Ile Asn Gly Lys Ala Ile His Leu Val Asn Asn Glu Ser Ser
1 5 10 15
Glu
(2) INFORMATION FOR SEQ ID NO:10:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(iii) ORIGINAL SOURCE: (A) ORGANISM:
(iv) FEATURE:
(A) NAME/KEY:
(B) LOCATION: 88...103
(C) OTHER INFORMATION: Cytochrome C Protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:
Ala Asn Glu Arg Ala Asp Leu Ile Ala Tyr Leu Gin Ala Thr Lys 1 5 10 15
(2) INFORMATION FOR SEQ ID NO:11:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(iii) ORIGINAL SOURCE:
(A) ORGANISM: Mycobacteria
(iv) FEATURE:
(A) NAME/KEY:
(B) LOCATION: 350...369
(C) OTHER INFORMATION: Heat Shock Protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:
Asp Gin Val His Phe Gin Pro Leu Pro Pro Ala Val Val Lys Leu Ser
1 5 10 15
Asp Ala Leu Ile 20
(2) INFORMATION FOR SEQ ID NO:12:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(iii) ORIGINAL SOURCE: (A) ORGANISM: Hen
(iv) FEATURE:
(A) NAME/KEY:
(B) LOCATION: 48...61
(C) OTHER INFORMATION: Egg White Lysozyme
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:
Asp Gly Ser Thr Asp Tyr Gly Ile Leu Gin Ile Asn Ser Arg 1 5 10
(2) INFORMATION FOR SEQ ID NO:13:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(iii) ORIGINAL SOURCE:
(A) ORGANISM: Streptococcus A
(iv) FEATURE:
(A) NAME/KEY:
(B) LOCATION: 308...319
(C) OTHER INFORMATION: M Protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:
Gin Val Glu Lys Ala Leu Glu Glu Ala Asn Ser Lys 1 5 10
(2) INFORMATION FOR SEQ ID NO:14:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(iii) ORIGINAL SOURCE:
(A) ORGANISM: Staphylococcus sp.
(iv) FEATURE:
(A) NAME/KEY:
(B) LOCATION: 81...100
(C) OTHER INFORMATION: Nuclease Protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:
Arg Thr Asp Lys Tyr Gly Arg Gly Leu Ala Tyr Ile Tyr Ala Asp Gly
1 5 10 15
Lys Met Val Asn 20
(2) INFORMATION FOR SEQ ID NO:15:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 4 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide (iii) ORIGINAL SOURCE: (A) ORGANISM:
(iv) FEATURE:
(A) NAME/KEY:
(B) LOCATION:
(C) OTHER INFORMATION:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:
Ala Ala Ala Leu
1
(2) INFORMATION FOR SEQ ID NO:16:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide (iii) ORIGINAL SOURCE:
(A) ORGANISM: Influenza PR8A Virus
(iv) FEATURE:
(A) NAME/KEY:
(B) LOCATION: 147...161
(C) OTHER INFORMATION: NP Protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:
Thr Tyr Gin Arg Thr Arg Ala Leu Val Arg Thr Gly Met Asp Pro 1 5 10 15
Claims
1. A method of preparing a substantially purified immunoglobulin molecule covalently conjugated to a polyethylene glycol molecule, the immunoglobulin molecule containing an immunogenic heterologous peptide selected from the group consisting of a T cell and a B cell epitope, the method comprising the steps of:
(i) enzymatically oxidizing a carbohydrate residue of the immunoglobulin molecule;
(ii) reacting the oxidized carbohydrate residue with an activated form of polyethylene glycol;
(iii) stabilizing the reaction product of step (ii) by reaction with a reducing agent;
(iv) removing unreacted polyethylene glycol from the products of the conjugation reaction of steps (i-iii) ; and
(v) removing residual adducts from the products of step (iv) by anion exchange chromatography.
2. The method of claim 1, wherein the activated form of polyethylene glycol is an amino acid derivative of polyethylene glycol.
3. The method of claim 2, wherein the activated form of polyethylene glycol is glycine- polyethylene glycol.
4. The method of claim 3, wherein the glycine polyethylene glycol is glycine-polyethylene glycol 3,500.
5. The method of claim 1, wherein the unre¬ acted polyethylene glycol is removed from the products of the conjugation reaction by size exclusion chromatography.
6. The method of claim 1, wherein the residual adducts are removed by anion exchange chroma¬ tography using high pressure liquid chromatography.
7. The method of claim 6, wherein residual adducts are removed by anion exchange chromatography using high pressure liquid chromatography, wherein a Q300 anion exchange column is used.
8. A composition comprising a substantially purified immunoglobulin molecule prepared using the method of claim 1.
9. A composition comprising a substantially purified immunoglobulin molecule prepared using the method of claim 2.
10. A composition comprising a substantially purified immunoglobulin molecule prepared using the method of claim 3.
11. A composition comprising a substantially purified immunoglobulin molecule prepared using the method of claim 4.
12. A substantially purified biologically active immunoglobulin molecule containing an immuno¬ genic heterologous peptide selected from the group consisting of a T cell and a B cell epitope, wherein the immunoglobulin molecule is covalently conjugated to an effective amount of polyethylene glycol for increasing the half-life of the immunoglobulin molecule without substantially decreasing the biological activity of the immunoglobulin molecule or the immun¬ ogenicity of the heterologous peptide, wherein the polyethylene glycol is conjugated to the immunoglobulin via a carbohydrate residue.
13. A method of preparing a non- immunoglobulin molecule covalently conjugated to a polyethylene glycol molecule, wherein the non- immunoglobulin molecule is a protein comprising at least one carbohydrate residue, the method comprising the steps of: (i) enzymatically oxidizing a carbohydrate residue of the protein;
(ii) reacting the oxidized carbohydrate residue with an activated form of polyethylene glycol;
(iii) stabilizing the reaction product of step (ii) by reaction with a reducing agent;
(iv) removing unreacted protein from the products of the conjugation reaction of steps (i-iii) ; and
(v) removing residual adducts from the products of step (iv) by anion exchange chromatography.
14. The method of claim 13, wherein the activated form of polyethylene glycol is an amino acid derivative of polyethylene glycol.
15. The method of claim 14, wherein the activated form of polyethylene glycol is glycine-poly- ethylene glycol.
16. A protein conjugated to polyethylene glycol by the method of claim 13.
17. A protein conjugated to polyethylene glycol by the method of claim 14.
18. A protein conjugated to polyethylene glycol by the method of claim 15.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU62550/96A AU6255096A (en) | 1995-06-07 | 1996-06-06 | Pegylated modified proteins |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47742195A | 1995-06-07 | 1995-06-07 | |
US08/477,421 | 1995-06-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996040731A1 true WO1996040731A1 (en) | 1996-12-19 |
Family
ID=23895850
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/008995 WO1996040731A1 (en) | 1995-06-07 | 1996-06-06 | Pegylated modified proteins |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU6255096A (en) |
WO (1) | WO1996040731A1 (en) |
Cited By (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5849535A (en) * | 1995-09-21 | 1998-12-15 | Genentech, Inc. | Human growth hormone variants |
US6333396B1 (en) | 1998-10-20 | 2001-12-25 | Enzon, Inc. | Method for targeted delivery of nucleic acids |
US6458355B1 (en) | 1998-01-22 | 2002-10-01 | Genentech, Inc. | Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates |
US6468532B1 (en) | 1998-01-22 | 2002-10-22 | Genentech, Inc. | Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates |
US6811785B2 (en) * | 2001-05-07 | 2004-11-02 | Mount Sinai School Of Medicine Of New York University | Multivalent MHC class II—peptide chimeras |
US6824782B2 (en) | 1997-04-30 | 2004-11-30 | Enzon, Inc. | Polyalkylene oxide-modified single chain polypeptides |
EP1545428A2 (en) * | 2002-09-20 | 2005-06-29 | Pharmacia Corporation | Process for decreasing aggregate levels of pegylated protein |
US7005504B2 (en) | 1998-01-22 | 2006-02-28 | Genentech, Inc. | Antibody fragment-peg conjugates |
US7125843B2 (en) | 2001-10-19 | 2006-10-24 | Neose Technologies, Inc. | Glycoconjugates including more than one peptide |
US7138371B2 (en) | 2001-10-10 | 2006-11-21 | Neose Technologies, Inc | Remodeling and glycoconjugation of peptides |
US7157277B2 (en) | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
US7179617B2 (en) | 2001-10-10 | 2007-02-20 | Neose Technologies, Inc. | Factor IX: remolding and glycoconjugation of Factor IX |
US7214776B2 (en) | 1999-01-21 | 2007-05-08 | Genentech, Inc. | Antibody fragment-polymer conjugates and uses of same |
US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US7226903B2 (en) | 2001-10-10 | 2007-06-05 | Neose Technologies, Inc. | Interferon beta: remodeling and glycoconjugation of interferon beta |
WO2007068412A2 (en) * | 2005-12-12 | 2007-06-21 | Ac Immune Sa | A beta 1-42 specific monoclonal antibodies with therapeutic properties |
US7265085B2 (en) | 2001-10-10 | 2007-09-04 | Neose Technologies, Inc. | Glycoconjugation methods and proteins/peptides produced by the methods |
US7265084B2 (en) | 2001-10-10 | 2007-09-04 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
US7297511B2 (en) | 2001-10-10 | 2007-11-20 | Neose Technologies, Inc. | Interferon alpha: remodeling and glycoconjugation of interferon alpha |
WO2007149802A2 (en) * | 2006-06-19 | 2007-12-27 | 3M Innovative Properties Company | Formulation for delivery of immune response modifiers |
US7399613B2 (en) | 2001-10-10 | 2008-07-15 | Neose Technologies, Inc. | Sialic acid nucleotide sugars |
US7405198B2 (en) | 2003-11-24 | 2008-07-29 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
US7439043B2 (en) | 2001-10-10 | 2008-10-21 | Neose Technologies, Inc. | Galactosyl nucleotide sugars |
US7470779B2 (en) | 2002-09-20 | 2008-12-30 | Pfizer Inc. | Process for decreasing aggregate levels of pegylated protein |
US7473680B2 (en) | 2001-11-28 | 2009-01-06 | Neose Technologies, Inc. | Remodeling and glycoconjugation of peptides |
EP2055189A1 (en) | 2003-04-09 | 2009-05-06 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
US7645860B2 (en) | 2006-03-31 | 2010-01-12 | Baxter Healthcare S.A. | Factor VIII polymer conjugates |
US7691603B2 (en) | 2003-04-09 | 2010-04-06 | Novo Nordisk A/S | Intracellular formation of peptide conjugates |
US7696163B2 (en) | 2001-10-10 | 2010-04-13 | Novo Nordisk A/S | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US7795210B2 (en) | 2001-10-10 | 2010-09-14 | Novo Nordisk A/S | Protein remodeling methods and proteins/peptides produced by the methods |
US7803777B2 (en) | 2003-03-14 | 2010-09-28 | Biogenerix Ag | Branched water-soluble polymers and their conjugates |
WO2011018515A1 (en) * | 2009-08-14 | 2011-02-17 | Novo Nordisk Health Care Ag | Method of purifying pegylated proteins |
WO2011064247A1 (en) * | 2009-11-24 | 2011-06-03 | Novo Nordisk Health Care Ag | Method of purifying pegylated proteins |
US7982010B2 (en) | 2006-03-31 | 2011-07-19 | Baxter International Inc. | Factor VIII polymer conjugates |
US7985839B2 (en) | 2006-03-31 | 2011-07-26 | Baxter International Inc. | Factor VIII polymer conjugates |
US8053561B2 (en) | 2006-03-31 | 2011-11-08 | Baxter International Inc. | Pegylated factor VIII |
US8124094B2 (en) * | 2005-04-08 | 2012-02-28 | Hanmi Holdings Co., Ltd. | Immunoglobulin Fc fragment modified by non-peptide polymer and pharmaceutical composition comprising the same |
US8268967B2 (en) | 2004-09-10 | 2012-09-18 | Novo Nordisk A/S | Glycopegylated interferon α |
US8361961B2 (en) | 2004-01-08 | 2013-01-29 | Biogenerix Ag | O-linked glycosylation of peptides |
EP2672259A1 (en) | 2008-05-13 | 2013-12-11 | Advanced Liquid Logic, Inc. | Droplet actuator devices, systems and methods |
US8637640B2 (en) | 2009-07-27 | 2014-01-28 | Baxter International Inc. | Blood coagulation protein conjugates |
US8637007B2 (en) | 2006-12-15 | 2014-01-28 | Baxter International Inc. | Factor VIIa-polysialic acid conjugate having prolonged in vivo half-life |
US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
US8791066B2 (en) | 2004-07-13 | 2014-07-29 | Novo Nordisk A/S | Branched PEG remodeling and glycosylation of glucagon-like peptide-1 [GLP-1] |
US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
US8841439B2 (en) | 2005-11-03 | 2014-09-23 | Novo Nordisk A/S | Nucleotide sugar purification using membranes |
US8877190B2 (en) | 2006-11-30 | 2014-11-04 | Abbvie Inc. | Aβ conformer selective anti-Aβ globulomer monoclonal antibodies |
US8895004B2 (en) | 2007-02-27 | 2014-11-25 | AbbVie Deutschland GmbH & Co. KG | Method for the treatment of amyloidoses |
US8911967B2 (en) | 2005-08-19 | 2014-12-16 | Novo Nordisk A/S | One pot desialylation and glycopegylation of therapeutic peptides |
US8916360B2 (en) | 2003-11-24 | 2014-12-23 | Novo Nordisk A/S | Glycopegylated erythropoietin |
US8945897B2 (en) | 2010-07-26 | 2015-02-03 | Baxter International Inc. | Materials and methods for conjugating a water soluble fatty acid derivative to a protein |
US8969532B2 (en) | 2006-10-03 | 2015-03-03 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography |
US8987419B2 (en) | 2010-04-15 | 2015-03-24 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
US9005625B2 (en) | 2003-07-25 | 2015-04-14 | Novo Nordisk A/S | Antibody toxin conjugates |
US9023992B2 (en) | 2004-05-04 | 2015-05-05 | Novo Nordisk Healthcare Ag | Hydrophobic interaction chromatography purification of factor VII polypeptides |
US9029331B2 (en) | 2005-01-10 | 2015-05-12 | Novo Nordisk A/S | Glycopegylated granulocyte colony stimulating factor |
US9050304B2 (en) | 2007-04-03 | 2015-06-09 | Ratiopharm Gmbh | Methods of treatment using glycopegylated G-CSF |
US9062101B2 (en) | 2010-08-14 | 2015-06-23 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
US9125880B2 (en) | 2002-12-26 | 2015-09-08 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates of interferon-beta with enhanced biological potency |
US9146244B2 (en) | 2007-06-12 | 2015-09-29 | Ac Immune S.A. | Polynucleotides encoding an anti-beta-amyloid monoclonal antibody |
US9150848B2 (en) | 2008-02-27 | 2015-10-06 | Novo Nordisk A/S | Conjugated factor VIII molecules |
US9175094B2 (en) | 2007-06-12 | 2015-11-03 | Ac Immune S.A. | Monoclonal antibody |
US9176150B2 (en) | 2003-01-31 | 2015-11-03 | AbbVie Deutschland GmbH & Co. KG | Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof |
US9187546B2 (en) | 2005-04-08 | 2015-11-17 | Novo Nordisk A/S | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
US9187532B2 (en) | 2006-07-21 | 2015-11-17 | Novo Nordisk A/S | Glycosylation of peptides via O-linked glycosylation sequences |
US9200049B2 (en) | 2004-10-29 | 2015-12-01 | Novo Nordisk A/S | Remodeling and glycopegylation of fibroblast growth factor (FGF) |
US9221900B2 (en) | 2010-07-30 | 2015-12-29 | Ac Immune S.A. | Methods for identifying safe and functional humanized antibodies |
US9403902B2 (en) | 2007-10-05 | 2016-08-02 | Ac Immune S.A. | Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody |
US9493499B2 (en) | 2007-06-12 | 2016-11-15 | Novo Nordisk A/S | Process for the production of purified cytidinemonophosphate-sialic acid-polyalkylene oxide (CMP-SA-PEG) as modified nucleotide sugars via anion exchange chromatography |
US9540432B2 (en) | 2005-11-30 | 2017-01-10 | AbbVie Deutschland GmbH & Co. KG | Anti-Aβ globulomer 7C6 antibodies |
US9795683B2 (en) | 2009-07-27 | 2017-10-24 | Lipoxen Technologies Limited | Glycopolysialylation of non-blood coagulation proteins |
US10208109B2 (en) | 2005-11-30 | 2019-02-19 | Abbvie Inc. | Monoclonal antibodies against amyloid beta protein and uses thereof |
US10300114B2 (en) * | 2003-06-26 | 2019-05-28 | Eyepoint Pharmaceuticals Us, Inc. | Bioerodible sustained release drug delivery systems |
US10350301B2 (en) | 2009-07-27 | 2019-07-16 | Baxalta Incorporated | Blood coagulation protein conjugates |
WO2021154854A1 (en) * | 2020-01-27 | 2021-08-05 | Bristol-Myers Squibb Company | Isoelectric focusing sample matrix |
-
1996
- 1996-06-06 WO PCT/US1996/008995 patent/WO1996040731A1/en active Application Filing
- 1996-06-06 AU AU62550/96A patent/AU6255096A/en not_active Abandoned
Non-Patent Citations (2)
Title |
---|
THE JOURNAL OF IMMUNOLOGY, 01 April 1995, Vol. 154, BRUMEANU et al., "Derivatization with Monomethoxypolyethylene Glycol of Igs Expressing Viral Epitopes Obviates Adjuvant Requirements", pages 3088-3095. * |
ZALIPSKY et al., "Use of Functionalized Poly(Ethylene Glycol)s for Modification of Polypeptides", In: POLY(ETHYLENE GLYCOL) CHEMISTRY: BIOTECHNICAL AND BIOMEDICAL APPLICATIONS, Edited by J. MILTON HARRIS, NEW YORK: PLENUM PRESS, 1992, pages 347-370. * |
Cited By (127)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6004931A (en) * | 1993-05-25 | 1999-12-21 | Genentech, Inc. | Method for inhibiting growth hormone action |
US6136563A (en) * | 1993-05-25 | 2000-10-24 | Genentech, Inc. | Human growth hormone variants comprising amino acid substitutions |
US5849535A (en) * | 1995-09-21 | 1998-12-15 | Genentech, Inc. | Human growth hormone variants |
US6057292A (en) * | 1995-09-21 | 2000-05-02 | Genentech, Inc. | Method for inhibiting growth hormone action |
US7632504B2 (en) | 1997-04-30 | 2009-12-15 | Enzon, Inc. | Polyalkylene oxide-modified single chain polypeptides |
US6872393B2 (en) | 1997-04-30 | 2005-03-29 | Enzon, Inc. | Polyalkylene oxide-modified single chain polypeptides |
US7150872B2 (en) | 1997-04-30 | 2006-12-19 | Enzon, Inc. | Polyalkylene oxide-modified single chain polypeptides |
US6824782B2 (en) | 1997-04-30 | 2004-11-30 | Enzon, Inc. | Polyalkylene oxide-modified single chain polypeptides |
US6468532B1 (en) | 1998-01-22 | 2002-10-22 | Genentech, Inc. | Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates |
US6458355B1 (en) | 1998-01-22 | 2002-10-01 | Genentech, Inc. | Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates |
US7005504B2 (en) | 1998-01-22 | 2006-02-28 | Genentech, Inc. | Antibody fragment-peg conjugates |
US6764853B2 (en) | 1998-10-20 | 2004-07-20 | Enzon Pharmaceuticals, Inc. | Method for targeted delivery of nucleic acids |
US6692942B2 (en) | 1998-10-20 | 2004-02-17 | Enzon, Inc. | Single-chain polypeptides for targeted delivery of nucleic acids |
US6333396B1 (en) | 1998-10-20 | 2001-12-25 | Enzon, Inc. | Method for targeted delivery of nucleic acids |
US7842789B2 (en) | 1999-01-21 | 2010-11-30 | Genentech, Inc. | Antibody fragment-polymer conjugates and uses of same |
US8147830B2 (en) | 1999-01-21 | 2012-04-03 | Genentech, Inc. | Antibody fragment-polymer conjugates and uses of same |
US7214776B2 (en) | 1999-01-21 | 2007-05-08 | Genentech, Inc. | Antibody fragment-polymer conjugates and uses of same |
US7507405B2 (en) | 1999-01-21 | 2009-03-24 | Genentech, Inc. | Antibody fragment-polymer conjugates and uses of same |
US8652468B2 (en) | 1999-01-21 | 2014-02-18 | Genentech, Inc. | Methods of binding TNF-α using anti-TNF-α antibody fragment-polymer conjugates |
US6811785B2 (en) * | 2001-05-07 | 2004-11-02 | Mount Sinai School Of Medicine Of New York University | Multivalent MHC class II—peptide chimeras |
US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
US7795210B2 (en) | 2001-10-10 | 2010-09-14 | Novo Nordisk A/S | Protein remodeling methods and proteins/peptides produced by the methods |
US7226903B2 (en) | 2001-10-10 | 2007-06-05 | Neose Technologies, Inc. | Interferon beta: remodeling and glycoconjugation of interferon beta |
US7416858B2 (en) | 2001-10-10 | 2008-08-26 | Neose Technologies, Inc. | Pharmaceutical compositions of glycoconjugates |
US7696163B2 (en) | 2001-10-10 | 2010-04-13 | Novo Nordisk A/S | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US7265085B2 (en) | 2001-10-10 | 2007-09-04 | Neose Technologies, Inc. | Glycoconjugation methods and proteins/peptides produced by the methods |
US7265084B2 (en) | 2001-10-10 | 2007-09-04 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
US7276475B2 (en) | 2001-10-10 | 2007-10-02 | Neose Technologies, Inc. | Remodeling and glycoconjugation of peptides |
US7297511B2 (en) | 2001-10-10 | 2007-11-20 | Neose Technologies, Inc. | Interferon alpha: remodeling and glycoconjugation of interferon alpha |
US7439043B2 (en) | 2001-10-10 | 2008-10-21 | Neose Technologies, Inc. | Galactosyl nucleotide sugars |
US7138371B2 (en) | 2001-10-10 | 2006-11-21 | Neose Technologies, Inc | Remodeling and glycoconjugation of peptides |
US7399613B2 (en) | 2001-10-10 | 2008-07-15 | Neose Technologies, Inc. | Sialic acid nucleotide sugars |
US7179617B2 (en) | 2001-10-10 | 2007-02-20 | Neose Technologies, Inc. | Factor IX: remolding and glycoconjugation of Factor IX |
US7125843B2 (en) | 2001-10-19 | 2006-10-24 | Neose Technologies, Inc. | Glycoconjugates including more than one peptide |
US7157277B2 (en) | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
US7473680B2 (en) | 2001-11-28 | 2009-01-06 | Neose Technologies, Inc. | Remodeling and glycoconjugation of peptides |
US7470779B2 (en) | 2002-09-20 | 2008-12-30 | Pfizer Inc. | Process for decreasing aggregate levels of pegylated protein |
EP1545428A2 (en) * | 2002-09-20 | 2005-06-29 | Pharmacia Corporation | Process for decreasing aggregate levels of pegylated protein |
CN1703421B (en) * | 2002-09-20 | 2010-06-23 | 法玛西亚公司 | Process for decreasing aggregate levels of PEG protein |
AU2003272585B2 (en) * | 2002-09-20 | 2009-12-10 | Pharmacia Corporation | Process for decreasing aggregate levels of pegylated protein |
EP1545428A4 (en) * | 2002-09-20 | 2006-03-01 | Pharmacia Corp | Process for decreasing aggregate levels of pegylated protein |
US9125880B2 (en) | 2002-12-26 | 2015-09-08 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates of interferon-beta with enhanced biological potency |
US10464976B2 (en) | 2003-01-31 | 2019-11-05 | AbbVie Deutschland GmbH & Co. KG | Amyloid β(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof |
US9176150B2 (en) | 2003-01-31 | 2015-11-03 | AbbVie Deutschland GmbH & Co. KG | Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof |
US8247381B2 (en) | 2003-03-14 | 2012-08-21 | Biogenerix Ag | Branched water-soluble polymers and their conjugates |
US7803777B2 (en) | 2003-03-14 | 2010-09-28 | Biogenerix Ag | Branched water-soluble polymers and their conjugates |
US7691603B2 (en) | 2003-04-09 | 2010-04-06 | Novo Nordisk A/S | Intracellular formation of peptide conjugates |
EP2055189A1 (en) | 2003-04-09 | 2009-05-06 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
US8853161B2 (en) | 2003-04-09 | 2014-10-07 | Novo Nordisk A/S | Glycopegylation methods and proteins/peptides produced by the methods |
US8063015B2 (en) | 2003-04-09 | 2011-11-22 | Novo Nordisk A/S | Glycopegylation methods and proteins/peptides produced by the methods |
EP2338333A2 (en) | 2003-04-09 | 2011-06-29 | BioGeneriX AG | Glycopegylation methods and proteins/peptides produced by the methods |
US10300114B2 (en) * | 2003-06-26 | 2019-05-28 | Eyepoint Pharmaceuticals Us, Inc. | Bioerodible sustained release drug delivery systems |
US9005625B2 (en) | 2003-07-25 | 2015-04-14 | Novo Nordisk A/S | Antibody toxin conjugates |
US8916360B2 (en) | 2003-11-24 | 2014-12-23 | Novo Nordisk A/S | Glycopegylated erythropoietin |
US7405198B2 (en) | 2003-11-24 | 2008-07-29 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
US8361961B2 (en) | 2004-01-08 | 2013-01-29 | Biogenerix Ag | O-linked glycosylation of peptides |
US9023992B2 (en) | 2004-05-04 | 2015-05-05 | Novo Nordisk Healthcare Ag | Hydrophobic interaction chromatography purification of factor VII polypeptides |
US10844110B2 (en) | 2004-05-04 | 2020-11-24 | Novo Nordisk Healthcare Ag | O-linked glycoforms of polypeptides and method to manufacture them |
US8791066B2 (en) | 2004-07-13 | 2014-07-29 | Novo Nordisk A/S | Branched PEG remodeling and glycosylation of glucagon-like peptide-1 [GLP-1] |
US8268967B2 (en) | 2004-09-10 | 2012-09-18 | Novo Nordisk A/S | Glycopegylated interferon α |
US9200049B2 (en) | 2004-10-29 | 2015-12-01 | Novo Nordisk A/S | Remodeling and glycopegylation of fibroblast growth factor (FGF) |
US10874714B2 (en) | 2004-10-29 | 2020-12-29 | 89Bio Ltd. | Method of treating fibroblast growth factor 21 (FGF-21) deficiency |
US9029331B2 (en) | 2005-01-10 | 2015-05-12 | Novo Nordisk A/S | Glycopegylated granulocyte colony stimulating factor |
US8124094B2 (en) * | 2005-04-08 | 2012-02-28 | Hanmi Holdings Co., Ltd. | Immunoglobulin Fc fragment modified by non-peptide polymer and pharmaceutical composition comprising the same |
US9187546B2 (en) | 2005-04-08 | 2015-11-17 | Novo Nordisk A/S | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
US8911967B2 (en) | 2005-08-19 | 2014-12-16 | Novo Nordisk A/S | One pot desialylation and glycopegylation of therapeutic peptides |
US8841439B2 (en) | 2005-11-03 | 2014-09-23 | Novo Nordisk A/S | Nucleotide sugar purification using membranes |
US10208109B2 (en) | 2005-11-30 | 2019-02-19 | Abbvie Inc. | Monoclonal antibodies against amyloid beta protein and uses thereof |
US9540432B2 (en) | 2005-11-30 | 2017-01-10 | AbbVie Deutschland GmbH & Co. KG | Anti-Aβ globulomer 7C6 antibodies |
US10323084B2 (en) | 2005-11-30 | 2019-06-18 | Abbvie Inc. | Monoclonal antibodies against amyloid beta protein and uses thereof |
WO2007068412A2 (en) * | 2005-12-12 | 2007-06-21 | Ac Immune Sa | A beta 1-42 specific monoclonal antibodies with therapeutic properties |
WO2007068412A3 (en) * | 2005-12-12 | 2007-08-09 | Ac Immune Sa | A beta 1-42 specific monoclonal antibodies with therapeutic properties |
EP2808032A1 (en) * | 2005-12-12 | 2014-12-03 | AC Immune S.A. | A beta 1-42 specific monoclonal antibodies with therapeutic properties |
US7645860B2 (en) | 2006-03-31 | 2010-01-12 | Baxter Healthcare S.A. | Factor VIII polymer conjugates |
US8067543B2 (en) | 2006-03-31 | 2011-11-29 | Baxter International Inc. | Factor VIII polymer conjugates |
US7982010B2 (en) | 2006-03-31 | 2011-07-19 | Baxter International Inc. | Factor VIII polymer conjugates |
US8071725B2 (en) | 2006-03-31 | 2011-12-06 | Baxter International Inc. | Factor VIII polymer conjugates |
US8071724B2 (en) | 2006-03-31 | 2011-12-06 | Baxter International Inc. | Factor VIII polymer conjugates |
US8071726B2 (en) | 2006-03-31 | 2011-12-06 | Baxter International Inc. | Factor VIII polymer conjugates |
US11020458B2 (en) | 2006-03-31 | 2021-06-01 | Takeda Pharmaceutical Company Limited | Factor VIII polymer conjugates |
US8053561B2 (en) | 2006-03-31 | 2011-11-08 | Baxter International Inc. | Pegylated factor VIII |
US8003760B2 (en) | 2006-03-31 | 2011-08-23 | Baxter International Inc. | Factor VIII polymer conjugates |
US8071727B2 (en) | 2006-03-31 | 2011-12-06 | Baxter International Inc. | Factor VIII polymer conjugates |
US7985839B2 (en) | 2006-03-31 | 2011-07-26 | Baxter International Inc. | Factor VIII polymer conjugates |
US8071728B2 (en) | 2006-03-31 | 2011-12-06 | Baxter International Inc. | Factor VIII polymer conjugates |
US7985838B2 (en) | 2006-03-31 | 2011-07-26 | Baxter International Inc. | Factor VIII polymer conjugates |
WO2007149802A2 (en) * | 2006-06-19 | 2007-12-27 | 3M Innovative Properties Company | Formulation for delivery of immune response modifiers |
WO2007149802A3 (en) * | 2006-06-19 | 2008-04-10 | 3M Innovative Properties Co | Formulation for delivery of immune response modifiers |
US9187532B2 (en) | 2006-07-21 | 2015-11-17 | Novo Nordisk A/S | Glycosylation of peptides via O-linked glycosylation sequences |
US8969532B2 (en) | 2006-10-03 | 2015-03-03 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography |
US8877190B2 (en) | 2006-11-30 | 2014-11-04 | Abbvie Inc. | Aβ conformer selective anti-Aβ globulomer monoclonal antibodies |
US9359430B2 (en) | 2006-11-30 | 2016-06-07 | Abbvie Inc. | Abeta conformer selective anti-Abeta globulomer monoclonal antibodies |
US9951125B2 (en) | 2006-11-30 | 2018-04-24 | Abbvie Inc. | Aβ conformer selective anti-Aβ globulomer monoclonal antibodies |
US8637007B2 (en) | 2006-12-15 | 2014-01-28 | Baxter International Inc. | Factor VIIa-polysialic acid conjugate having prolonged in vivo half-life |
US8895004B2 (en) | 2007-02-27 | 2014-11-25 | AbbVie Deutschland GmbH & Co. KG | Method for the treatment of amyloidoses |
US9050304B2 (en) | 2007-04-03 | 2015-06-09 | Ratiopharm Gmbh | Methods of treatment using glycopegylated G-CSF |
US9175094B2 (en) | 2007-06-12 | 2015-11-03 | Ac Immune S.A. | Monoclonal antibody |
US9146244B2 (en) | 2007-06-12 | 2015-09-29 | Ac Immune S.A. | Polynucleotides encoding an anti-beta-amyloid monoclonal antibody |
US9585956B2 (en) | 2007-06-12 | 2017-03-07 | Ac Immune S.A. | Polynucleotides encoding anti-amyloid beta monoclonal antibodies |
US9493499B2 (en) | 2007-06-12 | 2016-11-15 | Novo Nordisk A/S | Process for the production of purified cytidinemonophosphate-sialic acid-polyalkylene oxide (CMP-SA-PEG) as modified nucleotide sugars via anion exchange chromatography |
US9403902B2 (en) | 2007-10-05 | 2016-08-02 | Ac Immune S.A. | Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody |
US9150848B2 (en) | 2008-02-27 | 2015-10-06 | Novo Nordisk A/S | Conjugated factor VIII molecules |
EP2672260A1 (en) | 2008-05-13 | 2013-12-11 | Advanced Liquid Logic, Inc. | Droplet actuator devices, systems and methods |
EP2672259A1 (en) | 2008-05-13 | 2013-12-11 | Advanced Liquid Logic, Inc. | Droplet actuator devices, systems and methods |
US8637640B2 (en) | 2009-07-27 | 2014-01-28 | Baxter International Inc. | Blood coagulation protein conjugates |
US9492555B2 (en) | 2009-07-27 | 2016-11-15 | Baxalta Incorporated | Nucleophilic catalysts for oxime linkage |
US10350301B2 (en) | 2009-07-27 | 2019-07-16 | Baxalta Incorporated | Blood coagulation protein conjugates |
US9731024B2 (en) | 2009-07-27 | 2017-08-15 | Baxalta Incorporated | Nucleophilic catalysts for oxime linkage |
US9795683B2 (en) | 2009-07-27 | 2017-10-24 | Lipoxen Technologies Limited | Glycopolysialylation of non-blood coagulation proteins |
US11040109B2 (en) | 2009-07-27 | 2021-06-22 | Takeda Pharmaceutical Company Limited | Blood coagulation protein conjugates |
US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
US10414793B2 (en) | 2009-07-27 | 2019-09-17 | Baxalta Incorporated | Nucleophilic catalysts for oxime linkage |
US10772968B2 (en) | 2009-07-27 | 2020-09-15 | Lipoxen Technologies Limited | Glycopolysialylation of non-blood coagulation proteins |
US11564992B2 (en) | 2009-07-27 | 2023-01-31 | Takeda Pharmaceutical Company Limited | Nucleophilic catalysts for oxime linkage |
US10576160B2 (en) | 2009-07-27 | 2020-03-03 | Baxalta Incorporated | Nucleophilic catalysts for oxime linkage |
WO2011018515A1 (en) * | 2009-08-14 | 2011-02-17 | Novo Nordisk Health Care Ag | Method of purifying pegylated proteins |
US8697844B2 (en) | 2009-11-24 | 2014-04-15 | Novo Nordisk A/S | Method of purifying pegylated proteins |
WO2011064247A1 (en) * | 2009-11-24 | 2011-06-03 | Novo Nordisk Health Care Ag | Method of purifying pegylated proteins |
US9822171B2 (en) | 2010-04-15 | 2017-11-21 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
US8987419B2 (en) | 2010-04-15 | 2015-03-24 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
US8945897B2 (en) | 2010-07-26 | 2015-02-03 | Baxter International Inc. | Materials and methods for conjugating a water soluble fatty acid derivative to a protein |
US9221900B2 (en) | 2010-07-30 | 2015-12-29 | Ac Immune S.A. | Methods for identifying safe and functional humanized antibodies |
US9062101B2 (en) | 2010-08-14 | 2015-06-23 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
US10047121B2 (en) | 2010-08-14 | 2018-08-14 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
WO2021154854A1 (en) * | 2020-01-27 | 2021-08-05 | Bristol-Myers Squibb Company | Isoelectric focusing sample matrix |
Also Published As
Publication number | Publication date |
---|---|
AU6255096A (en) | 1996-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1996040731A1 (en) | Pegylated modified proteins | |
US5969109A (en) | Chimeric antibodies comprising antigen binding sites and B and T cell epitopes | |
AU668870B2 (en) | Targeted delivery of genes encoding immunogenic proteins | |
WO1996019584A9 (en) | Chimeric antibodies comprising antigen binding sites and b and t cell epitopes | |
JP3583420B2 (en) | Targeted immunization with bispecific reagents | |
RU2198895C2 (en) | Conjugate eliciting ability to activate immune system and pharmaceutical composition comprising indicated conjugate | |
US6197298B1 (en) | Modified binding molecules specific for T lymphocytes and their use as in vivo immune modulators in animals | |
AU5920096A (en) | Carbohydrate-mediated coupling of peptides to immunoglobulins | |
US8017584B2 (en) | GD3-mimetic peptides | |
CA2378866A1 (en) | Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens | |
CN101952414A (en) | Agents that engage antigen - presenting cells through dendritic cell asialoglycoprotein receptor (DC-ASGPR) | |
KR20070090011A (en) | Glycoconjugate vaccines containing peptidoglycan | |
AU1193999A (en) | J-chain and analogues as epithelial cell targeting conjugates | |
CS275838B6 (en) | Method for production of hybridoms used for monoclonal antigen against hiv virus producing | |
WO1999014244A1 (en) | Method of affinity cross-linking biologically active, immunogenic peptides to antibodies | |
JP2007516157A (en) | Glycosylated antigen / antibody or ligand / receptor specific exchanger | |
NO329917B1 (en) | Use of antibodies for the preparation of a pharmaceutical preparation for cancer expressing Ep-CAM | |
JPH05506221A (en) | HIV envelope polypeptide | |
Wolowczuk et al. | Protective immunity in mice vaccinated with the Schistosoma mansoni P-28-1 antigen. | |
Warren et al. | Synthetic glycopeptide-based vaccines | |
JP4651753B2 (en) | Vaccine consisting of carrier-bound antigen with labile binding | |
Brumeanu et al. | Immunopotency of a viral peptide assembled on the carbohydrate moieties of self immunoglobulins | |
Muller et al. | Specific antibody response towards predicted epitopes of the epidermal growth factor receptor induced by a thermostable synthetic peptide adjuvant conjugate. | |
Brumeanu et al. | Derivatization with monomethoxypolyethylene glycol of Igs expressing viral epitopes obviates adjuvant requirements. | |
JP3780421B2 (en) | Vaccine against human immunodeficiency virus and method for producing the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |